AU6428400A - Tricyclic analgesics - Google Patents

Tricyclic analgesics Download PDF

Info

Publication number
AU6428400A
AU6428400A AU64284/00A AU6428400A AU6428400A AU 6428400 A AU6428400 A AU 6428400A AU 64284/00 A AU64284/00 A AU 64284/00A AU 6428400 A AU6428400 A AU 6428400A AU 6428400 A AU6428400 A AU 6428400A
Authority
AU
Australia
Prior art keywords
piperidine
naphthalene
oxospiro
dihydro
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64284/00A
Inventor
Alain Calvet
Agnes Grouhel
Jacques Hamon
Henri Jacobelli
Jocelyne Puaud
Francois J. Roman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU6428400A publication Critical patent/AU6428400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

WO 00/75116 PCT/EP00/05783 -1 TRICYCLIC ANALGESICS FIELD OF THE INVENTION The invention relates to organic compounds characterized as having a fused bicyclic ring system substituted with a spiro nitrogen-containing third ring. 5 The compounds are effective for treating seizures and chronic pain in mammals. BACKGROUND OF THE INVENTION Although chronic pain is a frequent condition in the population, its pathophysiology is not well understood. One possibility is that nociceptive spinal sensory neurons generate inappropriate activity after injury. Spinal sensory 10 neurons become hyperexcitable and generate spontaneous impulses after injury in experimental animals, and in humans. Matzner and Devor (1992) proposed that the hyperexcitability associated with chronic pain results from an increase of Na channel density at the site of injury. It has also been hypothesized that, after nerve injury, changes in the kinetics and voltage-dependent characteristics of Na currents 15 contribute to the ectopic impulse generation and hyperexcitability of spinal sensory neurons. Dorsal root ganglion (DRG) neurons possess a complex mix of Na currents, including a fast tetrodotoxin-sensitive (TTX-S) current and a slow TTX-resistant (TTX-R) current. In rat DRG neurons, PGE 2 , adenosine and serotonin, three agents that produce hyperalgesia in vivo, increase the magnitude 20 of the TTX-R current, and shift its conductance/voltage relationship in a hyperpolarized direction (Gold et al., 1996). Following nerve injury, TTX-R currents are down regulated in DRG neurons, and, in the same animals, TTX-S currents are upregulated (Cummings and Waxman, 1997). Using a Na channel specific antibody, Devor et al. (1993) evidenced an accumulation of Na channels 25 in the neuroma resulting from a nerve section; the accumulation of Na channels at injured axonal tips may explain the ectopic channel excitability and the resulting WO 00/75116 PCT/EP00/05783 -2 pain and paresthesia which frequently complicate peripheral nerve injury in humans. Injury to the axons of spinal sensory neurons appear to modify Na currents, substantially altering their excitability; Thus, selective blockers of Na channels 5 can be used for the prevention or treatment of chronic pain in mammals. Sodium channel blockers have been shown effective in chronic pain syndromes, including trigeminal neuralgia, diabetic neuropathy, migraine prophylaxia and cancer pain (review by McQuay et al. ,1995, British Medical Journal, 1995; 311: 1047-1052, and references cited therein). 10 However, pain due to acute or chronic nerve injury is difficult to treat, and is often resistant to conventional analgesics. Such compounds include some local anesthetics and anticonvulsants, for example lidocaine, etidocaine, benzocaine, tetracain, riluzole, phenytoin, and gabapentin. Most of them, even though such agents modulate Na channels, have limited clinical use because of high risks of 15 adverse events. Lidocaine, for example, can cause cardiovascular collapse and resultant cardiac arrest. Benzocaine, can cause respiratory distress, as well as skin rash, erythema and oedema. The use of phenytoin for seizure disorders can result in hyperglycemia. Because there is no effective chemical treatment for neuropathic pain, e.g. 20 chronic pain, and since such pain is typically associated with diseases such as cancer, as well as severe physical injuries and diabetic neuropathy, the need continues to find compounds which can be utilized clinically without resulting in severe adverse events.
WO 00/75116 PCT/EP00/05783 -3 SUMMARY OF THE INVENTION The inventors have now discovered a series of tricyclic compounds which are potent antagonists of neuronal Na channels. The compounds are characterized as fused bicyclic ring systems having a spiro third ring substitution. 5 The invention therefore provides tricyclic compounds of Formula I: RI
R
2 R3
N-
N R5
R
4 (i) wherein: 10 R 1 is hydrogen or hydroxy;
R
2 is hydrogen or hydroxy; or
R
1 and R 2 together are oxygen; A is a bond, CH 2 , CH CH 3 , CH 2
CH
2 or C(CH3)2 ;
R
3 and R 4 are the same or different and are hydrogen, halo, C 1
-C
6 alkyl, 6 6 6 7 6 15 C1-C4 alkoxy, trifluoromethyl, NO 2 , COR 6 , COOR or NR6R 7 , wherein R and
R
7 are the same or different and are hydrogen, C 1
-C
6 alkyl or benzyl;
R
5 is hydrogen, CI-6 alkyl, C 2
-
6 alkenyl, C 3 -6 cycloalkyl, (O=C)-C 1
-
6 alkyl, (O=C)- C 2
-
6 alkenyl, (O=C)-C 3
-
6 cycloalkyl, wherein said alkyl, alkenyl and cycloalkyl groups can be substituted by 1, 2 or 3 groups selected from halo, C 3
-C
6 20 cycloalkyl, phenyl or substituted phenyl, and the pharmacentically acceptable salts thereof.
WO 00/75116 PCT/EP00/05783 -4 The compounds of the invention are useful in the clinical management and treatment of various conditions such as seizure disorders, epilepsy, neuroprotection, preferably for conditions such as cerebral ischemia, hypoxia and head trauma, local anesthesia, pain, preferably acute, chronic, neuropathic, visceral 5 and somatic pain, irritable bowel syndrom (IBS), the treatment of drug dependence, migraine and obsessional compulsive disorders. Preferred compounds are those of Formula I wherein R 5 is hydrogen, C 1 C 6 alkyl, optionally substituted with phenyl or a C 3
-C
6 cycloalkyl group. Other preferred compounds are those of Formula I wherein R 5 is C1-C 6 10 alkyl, optionally substituted with phenyl or a C 3
-C
6 cycloalkyl group. Other preferred compounds are those of Formula I wherein R 5 is hydrogen,
C
1
-C
6 alkyl, optionally substituted with phenyl or a C 3
-C
6 cycloalkyl group and
R
3 is hydrogen or C 1
-C
4 alkoxy. 15 Most preferred compounds of the invention are compounds of Formula I wherein R 1 and R 2 together are oxygen and A is CH 2 . Other most preferred compounds are those of formula I wherein R 5 is H,
C
1
-C
6 alkyl, optionally substituted with phenyl or a C 3
-C
6 cycloalkyl group and
R
3 is hydrogen or C l-C 4 alkoxy. 20 Another embodiment of this invention is a pharmaceutical formulation comprising a compound of Formula I admixed with a pharmaceutically acceptable carrier or diluent. A further embodiment of the present invention is a method for treating a 25 mammal suffering from pain and in need of treatment, comprising administering an effective amount of a compound of Formula I.
WO 00/75116 PCT/EP00/05783 -5 Still another embodiment of the invention is a method for treating a seizure disorder in a mammal in need of treatment, comprising administering a compound of Formula I. Methods of treatment of all the further indications referred to above also 5 fall within the scope of the present invention.
WO 00/75116 PCT/EP00/05783 -6 DETAILED DESCRIPTION OF THE INVENTION As used herein, the term "C 1
-C
6 alkyl" means a straight or branched carbon chain made up of from one to six carbon atoms. Examples of C 1
-C
6 alkyl groups include methyl, ethyl, isopropyl, sec-butyl, tert-butyl, isopentyl and n 5 hexyl.
"C
1
-C
6 alkoxy" means the foregoing alkyl groups bonded through oxygen, for example methoxy, isopropoxy, and n-hexyloxy.
"C
2
-C
6 alkenyl" means a straight or branched carbon chain having from two to six carbon atoms, with one carbon-carbon double bond present in the chain. 10 Examples include ethenyl, 2-propenyl, 1-methyl-3-pentenyl, 1-ethyl-2-butenyl, and 5-hexenyl.
"C
3
-C
6 cycloalkyl" means a non-aromatic cyclic ring having from three to six carbon atoms, examples being cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. 15 The foregoing alkyl, alkenyl and cycloalkyl groups may be substituted by 1, 2 or 3 groups selected from halo, unsubstituted C 3
-C
6 cycloalkyl, phenyl or substituted phenyl. "Halo" means chloro, bromo, fluoro and iodo. "Substituted phenyl" means a phenyl group having 1, 2 or 3 substituents selected from halo, hydroxy, nitro, unsubstituted C 1
-C
6 alkyl, unsubstituted C 1
-C
6 alkoxy, and NH 2 . 20 Examples of C 1
-C
6 alkyl groups substituted with cycloalkyl thus include cyclopropylmethyl, 1-cyclobutylethyl, 3-cyclohexylbutyl and 3,3-dicyclohexyl propyl. Alkyl groups substituted with halo include chloromethyl, 1,2-dibromo ethyl, trifluoromethyl, and 1-bromo-3-chloro-6-iodohexyl. Alkyl groups sub stituted with phenyl or with substituted phenyl include benzyl, 1-phenylpropyl, 25 1-methyl-3-phenyl-butyl, 3-chlorophenylmethyl, 2,3-dimethoxybenzyl, 3-(2 methyl-5-fluoro-6-nitrophenyl)-butyl, and 3,3-diphenylpropyl. Examples of substituted C 2
-C
6 alkenyl groups include 2-cyclobutylethenyl, 3-phenyl-2-butenyl, 1,1-dimethyl-3-chloro-3-butenyl, 4,4-diphenyl-3-butenyl, 2- WO 00/75116 PCT/EP00/05783 -7 (3-chlorophenyl)-3-cylclobutyl-4-hexenyl, and 1,2-difluoro-3-(2-phenyl cyclobutyl)-4-pentenyl. Examples of substituted C 3
-C
6 cycloalkyl groups include 3-cyclo pentylcyclohexyl, 2-phenylcyclobutyl, 3-chlorocyclopentyl, 2,2-dibromo-3-nitro 5 cyclohexyl, and 2,2-di-(3-methoxyphenyl)-cyclopropyl. Examples of substituted C 1
-C
6 alkoxy groups include trichloromethoxy, cyclopropylmethoxy, 1-methyl-2-phenylpropoxy and 2,3-di-(2,4-dinitrophenyl) hexyloxy. The alkyl, alkenyl and cycloalkyl substituent groups can be bonded 10 through a carbonyl (O=C) group. Examples include acetyl, pivaloyl, 1-oxo-3 pentenyl, 1-oxocyclobutylmethyl, 1-oxo-3-phenyl-4-cyclohexylpentyl, and 1-oxo (3-phenylcyclopentyl)-methyl. "-A-" in Formula I is defined as a bond, -CH 2 -, -CH-CH3, -CH-(CH 3
)
2 and
-CH
2
CH
2 -; the invention compounds can thus have the following general 15 structures: NR2 R4 N , R5
R
3 (la) NR2
R
4 NbR 5
R
3 (Ib) WO 00/75116 PCT/EP00/05783 -8 1R2
R
4 R5 RN R3
CH
3 (Ic) NR2
R
4 N R 5
R
3 (Id) Preferred compounds of the present invention include the following: 5 3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; l'-cyclopropylmethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1'-cyclobutylmethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2(1H),4'-piperidine]; 1 '-cyclohexylmethyl-3,4-Dihydro-I -oxospiro[naphthalene-2(1H),4'-piperidine]; I '-phenylethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2(1H),4'-piperidine]; 10 1'-cyclopropylethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1'-cinnamyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1 '-(3,3-diphenylpropyl)-3,4-Dihydro-l1-oxospiro[naphthalene-2(1H),4' piperidine]; 1 '-(cyclopropylmethyl)-3,4-Dihydro-5,7-dimethyl-1 -oxospiro [naphthalene 15 2(1H),4'-piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-6-methoxy-l1-oxospiro[naphthalene-2(1H),4' piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-5-methoxy-I -oxospiro[naphthalene-2(1H),4' piperidine]; 20 1l'-(cyclopropylmethyl)-3,4-Dihydro-7-methoxy-I -oxospiro[naphthalene-2(1H),4' piperidine]; WO 00/75116 PCT/EP00/05783 -9 1 '-(cyclopropylmethyl)-3,4-Dihydro-7-nitro- I -oxospiro[naphthalene-2( 1H),4' piperidine]; 1l'-(cyclopropylmethyl)-7-Amino-3,4-dihydro- I -oxospiro[naphthalene-2(1H),4' piperidine]; 5 1l'-(cyclopropylmethyl)-7-Chloro-3,4-dihydro- I -oxospiro[naphthalene-2(1H),4' piperidine]; 3,4-dihydro -1 '-methyl- 1-oxospiro(naphthalene-2(1H),4'-piperidine); 1'- allyl - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine); 3,4-dihydro -1'-( 2-methylpropyl)- 1 -oxospiro(naphthalene-2(1H),4'-piperidine); 10 1'-cyclopropionyl- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine) ; 3,4-dihydro -I -oxospiro(naphthalene-2(1H),4'-piperidine) - 1' (trans-2-phenyl methylcyclopropyl ) ; 3,4-dihydro -1 '-benzyl- I -oxospiro(naphthalene-2(1H),4'-piperidine); 3,4-dihydro -1 '-(di-p-fluorobenzhydryl)- 1 -oxospiro(naphthalene-2(1H),4' 15 piperidine); 1 '-cyclopropylmethyl- 1,3,4-trihydro -1-hydroxy-spiro(naphthalene-2(1H),4' piperidine); l'-cyclopropylmethyl- 1,2,3,4-tetrahydro -spiro(naphthalene-2(1H),4'-piperidine); 1 '-cyclopropylmethyl-1,3-dihydro- 1 -oxospiro-[ 2H-indene-2,4'-piperidine]; 20 1 '-(cyclopropylmethyl)-8,9-dihydrospiro[6H-benzocycloheptene-6,4'-piperidin] 5(7H)-one; 1l'-cyclopropylmethyl- 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' piperidine); 6-chloro-1 '-cyclopropylmethyl- 3,4-dihydro -1-oxospiro(naphthalene-2(1 H),4' 25 piperidine); 1'-cyclopropylmethyl- 3,4-dihydro -6-fluoro- 1 -oxospiro(naphthalene-2(1H),4' piperidine); 1'-cyclopropylmethyl- 3,4-dihydro -6,7-dimethoxy- 1 -oxospiro(naphthalene 2(1H),4'-piperidine); 30 1'-(1 -cyclopropyl- 1-ethyl)- 3,4-dihydro -1-oxospiro(naphthalene-2( 1H),4' piperidine); l'-(3-pentene)- 3,4-dihydro -1 -oxospiro(naphthalene-2(1H),4'-piperidine; WO 00/75116 PCTIEP00/05783 -10 1'-( 3-phenylpropyl )- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine; 1 '-cinnamyl- 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2( 1H),4' piperidine; S'-cyclopropylethyl - 3,4-dihydro -5-methoxy- 1 -oxospiro(naphthalene-2( 1H),4' 5 piperidine; 1 '-cyclobutylmethyl - 3,4-dihydro -5-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine ; 1 '-cyclohexylmethyl - 3,4-dihydro -5-methoxy- 1-oxospiro(naphthalene-2(1H),4' piperidine ; 10 1 '-cinnamyl - 3,4-dihydro -5-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 1 '-( 2-phenylethyl) - 3,4-dihydro -5-methoxy- I -oxospiro(naphthalene-2( 1H),4' piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' 15 piperidine ; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -5-methoxy- 1 -oxospiro(naphthalene 2(1H),4'-piperidine; l'-cyclopropylethyl - 3,4-dihydro -6-methoxy-l-oxospiro(naphthalene-2(1H),4' piperidine; 20 1'-cyclobutylmethyl - 3,4-dihydro -6-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; l'-cyclohexylmethyl - 3,4-dihydro -6-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 1'-cinnamyl - 3,4-dihydro -6-methoxy- I -oxospiro(naphthalene-2(1H),4' 25 piperidine; 1'-( 2-phenylethyl) - 3,4-dihydro -6-methoxy-1l-oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -6-methoxy-l-oxospiro(naphthalene-2(1H),4' piperidine; 30 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -6-methoxy-1-oxospiro(naphthalene 2(1H),4'-piperidine ; WO 00/75116 PCTIEP00/05783 -11 1'-cyclopropylethyl - 3,4-dihydro -7-methoxy- I -oxospiro(naphthalene-2(1H),4' piperidine; 1 '-cyclobutylmethyl - 3,4-dihydro -7-methoxy- I -oxospiro(naphthalene-2(1H),4' piperidine; 5 1 '-cyclohexylmethyl - 3,4-dihydro -7-methoxy- 1 -oxospiro(naphthalene-2( 1H),4' piperidine; S'-cinnamyl - 3,4-dihydro -7-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 2-phenylethyl) - 3,4-dihydro -7-methoxy- 1 -oxospiro(naphthalene-2(1H),4' 10 piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -7-methoxy-l-oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -7-methoxy-1-oxospiro(naphthalene 2(1H),4'-piperidine ; 15 1'-cyclopropylethyl - 3,4-dihydro -4-methyl-1-oxospiro(naphthalene-2(1H),4' piperidine; 1'-cyclobutylmethyl - 3,4-dihydro -4-methyl-1-oxospiro(naphthalene-2(1H),4' piperidine; 1'-cyclohexylmethyl - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' 20 piperidine; l'-cinnamyl - 3,4-dihydro -4-methyl-I -oxospiro(naphthalene-2(1H),4'-piperidine; 1'-( 2-phenylethyl) - 3,4-dihydro -4-methyl- -oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' 25 piperidine; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' piperidine; 6-chloro- 1'-cyclopropylethyl - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine; 30 6-chloro -1 '-cyclobutylmethyl - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine; WO 00/75116 PCT/EP00/05783 -12 6-chloro -1 '-cyclohexylmethyl - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine; 6-chloro -1 '-cinnamyl - 3,4-dihydro -1 -oxospiro(naphthalene-2( 1H),4'-piperidine; 6-chloro -1 '-( 2-phenylethyl) - 3,4-dihydro -1-oxospiro(naphthalene-2( 1H),4' 5 piperidine; 6-chloro -1 '-( 3-phenylpropyl) - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine ; and 6-chloro -1 '-( 3,3'diphenylpropyl) - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine. 10 3,4-Dihydro-6-methoxy- 1-oxospiro[naphthalene-2(1H),4'-piperidine] More preferred compounds of the invention include the following: 15 l'-cyclopropylmethyl-3,4-Dihydro-l1-oxospiro[naphthalene-2(1H),4'-piperidine]; 1'-cyclopropylethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2(1H),4'-piperidine]; 1'-cinnamyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1 '-(3,3-diphenylpropyl)-3,4-Dihydro-l1-oxospiro[naphthalene-2(1H),4' piperidine]; 20 1 '-(cyclopropylmethyl)-3,4-Dihydro-5,7-dimethyl- I -oxospiro[naphthalene 2(1 H),4'-piperidine]; 1l'-(cyclopropylmethyl)-3,4-Dihydro-6-methoxy- 1 -oxospiro[naphthalene-2(1 H),4' piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-5-methoxy- 1 -oxospiro[naphthalene-2(1 H),4' 25 piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-7-methoxy-1 -oxospiro[naphthalene-2(1H),4' piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-7-nitro- I -oxospiro[naphthalene-2(1 H),4' piperidine]; 30 1 '-(cyclopropylmethyl)-7-Amino-3,4-dihydro- I -oxospiro [naphthalene-2( 1H),4' piperidine]; WO 00/75116 PCT/EP00/05783 -13 1 '-(cyclopropylmethyl)-7-Chloro-3,4-dihydro- I -oxospiro[naphthalene-2( 1H),4' piperidine]; 1'-cyclopropylmethyl- 1,3,4-trihydro-1-hydroxy-spiro(naphthalene-2(1H),4' piperidine); 5 1 '-cyclopropylmethyl- 1,2,3,4-tetrahydro -spiro(naphthalene-2(1H),4'-piperidine) 1 '-cyclopropylmethyl-1,3-dihydro- 1 -oxospiro-[ 2H-indene-2,4'-piperidine]; 1 '-(cyclopropylmethyl)-8,9-dihydrospiro[6H-benzocycloheptene- 6
,
4 '-piperidin] 5(7H)-one; 1'-cyclopropylmethyl- 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' 10 piperidine); 6-chloro-l'-cyclopropylmethyl- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine); 1 '-cyclopropylmethyl- 3,4-dihydro -6-fluoro- 1-oxospiro(naphthalene-2(1H),4' piperidine); 15 1'-cyclopropylmethyl- 3,4-dihydro -6,7-dimethoxy- 1-oxospiro(naphthalene 2(1H),4'-piperidine); 1'-(1-cyclopropyl-1-ethyl)- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine); 1'-(3-pentene)- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine; 20 1'-( 3-phenylpropyl )- 3,4-dihydro -1 -oxospiro(naphthalene-2(1H),4'-piperidine; l'-cinnamyl- 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; I'-cyclopropylethyl - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 25 l'-cyclobutylmethyl - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 1'-cinnamyl - 3,4-dihydro -5-methoxy- I -oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' 30 piperidine ; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene 2(1H),4'-piperidine; WO 00/75116 PCT/EP00/05783 -14 l'-cyclopropylethyl - 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine ; l'-cyclobutylmethyl - 3,4-dihydro -6-methoxy- I -oxospiro(naphthalene-2(1H),4' piperidine; 5 1'-cinnamyl - 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 1 '-( 3-phenylpropyl) - 3,4-dihydro -6-methoxy- I -oxospiro(naphthalene-2(1H),4' piperidine; 1 '-( 3,3'diphenylpropyl) - 3,4-dihydro -6-methoxy-1-oxospiro(naphthalene 10 2(1H),4'-piperidine ; 1'-cyclopropylethyl - 3,4-dihydro -7-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine ; 1'-cinnamyl - 3,4-dihydro -7-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 15 1'-( 3-phenylpropyl) - 3,4-dihydro -7-methoxy-1-oxospiro(naphthalene-2(1H), 4
'
piperidine; 1'-(3,3'diphenylpropyl) -3,4-dihydro -7-methoxy- 1-oxospiro(naphthalene 2(1H),4'-piperidine; 1 '-cyclopropylethyl -3,4-dihydro-4-methyl- 1 -oxospiro(naphthalene-2( 1 H),4' 20 piperidine; 1 '-cyclobutylmethyl -3,4-dihydro -4-methyl-1 -oxospiro(naphthalene-2(1H),4' piperidine; 1 '-cinnamyl - 3,4-dihydro -4-methyl- 1-oxospiro(naphthalene-2( 1H),4'-piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' 25 piperidine; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -4-methyl- 1-oxospiro(naphthalene-2(1H),4' piperidine; 6-chloro-1 '-cyclopropylethyl - 3,4-dihydro -1 -oxospiro(naphthalene-2(1H),4' piperidine; 30 6-chloro -1'-cinnamyl - 3,4-dihydro - 1 -oxospiro(naphthalene-2(1H),4'-piperidine; 6-chloro - 1'-( 3-phenylpropyl) - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine ; and WO 00/75116 PCT/EP00/05783 -15 6-chloro -1 '-( 3,3'diphenylpropyl) - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine. 3,4-Dihydro-6-methoxy-l1-oxospiro[naphthalene-2(1H),4'-piperidine] 5 Most preferred compounds of the invention include the following: 1 '-cyclopropylmethyl-3,4-Dihydro- I -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1 '-cyclopropylethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2(1H),4'-piperidine]; 1 '-cinnamyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1 '-(3,3-diphenylpropyl)-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1 H),4' 10 piperidine]; 1l'-(cyclopropylmethyl)-3,4-Dihydro-6-methoxy-l1-oxospiro[naphthalene-2(1H),4' piperidine]; 1'-( 3-phenylpropyl )- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine; l'-cyclobutylmethyl - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' 15 piperidine ; 1'-cyclopropylethyl - 3,4-dihydro -6-methoxy- 1-oxospiro(naphthalene-2(1H),4' piperidine; l'-cyclobutylmethyl - 3,4-dihydro -6-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 20 1'-( 3-phenylpropyl) - 3,4-dihydro -6-methoxy-1-oxospiro(naphthalene-2(1H),4' piperidine; 1l'-cyclopropylethyl - 3,4-dihydro -7-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 3,4-Dihydro-6-methoxy- 1 -oxospiro[naphthalene-2(1H),4'-piperidine] 25 The compounds of Formula I are characterized by being bicyclic rings having a spiro ring as a substituent group. The spiro ring contains a nitrogen atom (i.e. N-R5), which can be basic in nature when R 5 is a group such as alkyl, alkenyl or cycloalkyl. Such basic compounds readily form pharmaceutically acceptable 30 salts by reaction with common inorganic and organic acids. Typical acids utilized to form the pharmaceutically acceptable salts of the invention include hydro- WO 00/75116 PCTIEP00/05783 -16 chloric, sulfuric, sulfamic , phosphoric , citric , succinic , glutamic , maleic , lactic, tartaric, p-toluenesulfonic, benzoic , oxalic and salicyclic acid. The salts are prepared by simply contacting the spiro base with the appropriate acid, generally in a solvent such as methanol or diethyl ether. The salts generally are highly 5 crystalline, readily precipitate, and are recovered by filtration. They can be further purified if desired by recrystallization from common solvents such as methanol, ethyl acetate, acetone and tetrahydrofuran. The invention compounds of Formula I are readily prepared by methodo logies well known in the art of organic chemistry. It is preferred to simply first 10 prepare a compound wherein R 5 is hydrogen, and then react this compound with 5 R5-alkylating or -acylating agents. Such reaction is shown in scheme 1 below: Scheme 1 1 1 R2
R
4 NH
R
4 N ..- R 5 NHN R A+
L-R
5 A A
R
3 R 3 15 1 2 3 4 where R , R , R , R , and A have the meanings given above, and " L " is a normal leaving group (e.g. halo such as chloro or bromo, or a silyl derivative such as trimethylsilyl). The foregoing reaction is carried out by combining approximately 20 equimolar quantities of the spiro amine with the alkylating or acylating agent (i.e. L-R5), generally in an unreactive organic solvent such as tetrahydrofuran, dimethylsulfoxide, or N,N-dimethylformamide. A base such as triethylamine or NaHCO 3 can be utilized to act as an acid scavenger if desired. The reaction typically is substantially complete after about 2 - 20 h, when conducted at a 25 temperature is about 25 0 C to about 60 0 C. The product is readily isolated by removing the reaction solvent, and further purification can be achieved if desired by normal means such as salt formation, crystallization, and chromatography.
WO 00/75116 PCT/EP00/05783 -17 The required starting material, i.e. the spiro amine, can be synthesized from readily available reactants, utilizing any of several methods: -In one method, an N-protected form of a derivatized diethylamine is reacted with a bicyclic ketone according to scheme 2: 5 Scheme 2 HOBr Br HO BrHBr Protecting Br H~r group NH - NH g N-P HO Br Br 0
R
3 0 3 0 P0 A R N R3 NH R HCI \ NaH / DMF AA
R
4
R
4 In the above scheme 2, P is an amine-protecting group that is easily 10 removed, for example ethoxycarbonyl or benzyl. The protected diethylamine derivative is readily reacted with a bicyclic ketone in the presence of a strong base such as NaH. This reaction results in formation of the spiro amino derivative, which is readily de-protected by conventional means, for instance by reaction with hydrochloric acid. 15 Scheme 2 illustrates the preparation of keto substituted starting materials, i.e. where RI and R 2 together are oxo. Such compounds are easily converted to the corresponding alcohol ( R 1 is H, R 2 is OH ) by reaction with a reducing agent such as NaBH 4 , generally in a solvent such as methanol or ethanol.
WO 00/75116 PCT/EP00/05783 -18 The alcohol can be further reduced by catalytic hydrogenation, for example by reaction with hydrogen gas in the presence of 10% palladium on carbon. These reactions are illustrated in Scheme 3 5 Scheme 3
R
4 R2
R
4 H OH NH orL NH orL NaBH 4 A A
R
3 R 3
H
2 /Pd-C R4 NH or L A
R
3 The invention compounds of Formula I can alternatively be prepared by starting with a suitably substituted piperidine derivative, as shown in Scheme 4 10 Scheme 4 O R4 R4 N R5
HO
2 C ~ PC1 5 A N -R 5 TiC4 A /A AiI Solvent
R
3
R
3 R The cyclization reaction is accomplished by reacting the substituted piperidine with strong dehydrating agents such as phosphorus pentachloride and titanium 15 tetrachloride, generally in an unreactive organic solvent such as benzene, toluene, xylene, or chloroform. The reaction normally is complete within 2 h when carried out at a temperature of 30 0 C to 60'C.
WO 00/75116 PCT/EP00/05783 -19 The cyclized product is a compound of Formula I wherein R and R together are oxo, which, as noted above in Scheme 3, can be reduced to the corresponding alcohol or alkane ( R 1 and R both hydrogen). The substituted piperidine required for the above reaction is readily 5 prepared as shown in Scheme 5: Scheme 5 0 C N Protecting N-P NH > CH 3 -O
CH
3 -0 group
R
4 R4 CH 3 0O NHRA Br R4 NH R A O R deprotection R4 N-P lkylation or cyclization A R4 R N-PR A R R4 ONH R4 O R deprotection NH N cyclizationalkyation or co A acylation R A R R In Scheme 5, the methyl 4-piperidine formate is reacted with an amine-protecting 10 agent (i.e. to insert P ). Typical amine-protecting groups include tert-butoxy carbonyl, benzyl and trimethylsilyl. The protected piperidine derivative is next WO 00/75116 PCT/EP00/05783 -20 reacted with a phenyl alkyl halide, for example phenylethyl bromide (where A is
CH
2 ) or 2-phenylpropyl iodide (where A is CH-CH 3 ) or 3-phenylpropyl iodide (where A is CH 2
CH
2 ), in the presence of a strong base such as NaH or lithium diisopropylamide (LDA), generally in an unreactive solvent such as tetrahydro 5 furan, or benzene. The reaction, carried out at about -20 0 C, generally is sub stantially complete after about 2 - 4 h. The alkylated piperidine can then be deprotected (removal of the L-protecting group) and cyclized by reaction with PCl 5 and TiCl 4 , or it can be cyclized first, and the L-protecting group subsequently removed. 10 The following detailed examples illustrate the synthesis of specific compounds provided by this invention. The examples are representative only, and are not intended to be limiting in any respect. EXAMPLE 1 15 3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine] 0 NH Stage 1: Bis(2-bromoethyl)amine hydrobromide. 157.5 g (1.5 mol) of diethanolamine and then, with stirring, 1.35 1 of 48% HBr (exothermic reaction) are introduced into a 2 1 three-necked flask which can be 20 equipped either for reflux or for distillation. The solution is heated at a bath temperature of 180-200 0 C, in order to distill off a volume of 350 ml at a vapour temperature of 122oC. The device is adjusted to the reflux position and is maintained for 1 h. A further distillation is carried out as above, in order to collect a distillate of 465 ml. The device is again adjusted for reflux for 3.75 h and then 25 400 ml are distilled off. The mixture is cooled and 300 ml of ethyl acetate are added to the residue. The suspension is stirred for 1 h in an ice bath. The precipitate is filtered off and then washed with ethyl acetate. 367 g of a white crystalline product are obtained. Yd = 78.5%, M.p. (oC) = 130-135 0
C.
WO 00/75116 PCT/EP00/05783 -21 Stage 2: Ethyl bis(2-bromoethyl)carbamate. 367 g (1.17 mol) of the product obtained in the preceding stage and then 108 ml, i.e. 122.6 g (1.13 mol), of ethyl chloroformate are added, with stirring, to a 4 1 5 reactor containing 1.8 1 of a water/ice mixture. Approximately 1.3 1 of a 2N sodium hydroxide solution are run into the solution over 5 min in order to achieve a continuing pH of 11, while maintaining a temperature below 5oC. The mixture is stirred for 5 min and then acidified to pH 1 with concentrated HC1. Extraction is carried out with 3 times 1 1 of ethyl ether. The organic phase is washed with 3 10 times 500 ml of demineralized water and then dried over Na 2
SO
4 . The solvent is evaporated. The residue is chromatographed by eluting with CH 2 Cl 2 . 208.5 g of product are obtained. Yd = 58%, TLC (CH 2 C1 2 ): Rrf = 0.6, N.M.R.: CDC1 3 'H ((ppm): 1.2 (t, 3H), 3.4-3.55 (m, 4H), 3.6-3.7 (m, 4H), 4.1-4.2 (q, 2H)). 15 Stage 3: Ethyl 3,4-dihydro-l-oxospiro [naphthalene-2(1H),4'-piperidine]-l1' carboxylate. 69 g (0.472 mol) of 1-tetralone and 234 ml of DMF, dried beforehand over molecular sieve, are introduced into a reactor which is protected from moisture 20 and which is under an inert atmosphere. The solution is cooled to -15 0 C with a dry ice/acetone bath and 34.6 g (1.15 mol) of 80% sodium hydride, as a dispersion in mineral oil, are added thereto. The temperature is allowed to rise to approximately 20-25'C (exothermic reaction). The reaction mixture is stirred for 1.5 h at a temperature below 30'C. 25 At the same time, a solution of 208 g (0.69 mol) of ethyl bis(2 bromoethyl)carbamate in 234 ml of DMF (dried beforehand over molecular sieve) is cooled, in a reactor which is protected from moisture and which is under an inert atmosphere, to -25'C with a dry ice/acetone bath. The reaction liquors, prepared at the same time, are introduced by transfer under nitrogen and run in 30 over 10 min at a temperature of -25oC. The temperature is allowed to rise (exothermic reaction with rise in the temperature to 45 0 C). The reaction mixture is then cooled in order to maintain it at approximately 30 0 C. It is subsequently WO 00/75116 PCT/EP00/05783 -22 brought to 50 0 C for 2 h and then the solvent is evaporated at 50'C under a vacuum of less than 1 mm Hg. The residue is taken up in 1.2 1 of ice-cold water and extracted with 3 times 600 ml of ether. The organic phase is washed with 3 times 500 ml of demineralized water and then dried over Na 2
SO
4 . After evaporating the 5 solvent, a dark brown oily residue is obtained which is purified by fast chromatography by eluting with CH 2 Cl 2 gradually enriched with acetone. 57.7 g (0.2 mol) of product are obtained (Yd = 42.5%), TLC (97/3 CH 2 C1 2 /acetone): Rf = 0.45. N.M.R.: CDCl 3 'H ((ppm): 1.15 (t, 3H), 1.4 (min, 2H), 1.8-2.0 (m, 4H), 2.85-2.95 10 (min, 2H), 3.45-3.55 (m, 4H), 4.0-4.1 (q, 2H), 7.1 (d, 1H), 7.2 (dd, 1H), 7.35 (dd, 1H), 7.9 (d, 1H)). Stage 4: 3,4-Dihydro- 1-oxospiro[naphthalene-2(1H),4'-piperidine). 57.7 g (0.2 mol) of ethyl 3,4-dihydro-l-oxospiro-[naphthalene-2(1H),4' 15 piperidine]-1l'-carboxylate and then 1.6 1 of 6N HCI are introduced into a reactor. The mixture is stirred and brought to reflux for 14 h. It is then cooled and extracted with twice 500 ml of ethyl ether. The aqueous phase is basified while cold with NaOH and extracted with 3 times 500 ml of ethyl ether. The organic phase is washed and dried over Na 2
SO
4 . After evaporating the solvent, the residue 20 is purified by chromatography by eluting with CH 2 Cl 2 gradually enriched with methanol containing 10% NH40H. Weight: 31 g, Yd = 72%, TLC (90/10 CH 2 Cl 2 /MeOH containing 10% NH 4 OH): Rf = 0.2-0.35. N.M.R.: CDCl 3 'H ((ppm) Base: 1.35-1.45 (m, 2H), 1.8-1.9 (min, 2H), 2.0 (t, 2H), 25 2.1 (s, 1H), 2.75-2.85 (min, 2H), 2.85-3.0 (m, 4H), 7.1 (d, 1H), 7.2 (dd, 1H), 7.35 (dd, 1H), 7.9 (d, 1H)). The hydrochloride is prepared by addition of approximately 5N ethereal hydrochloric acid to a solution of the product in CH 2
CI
2 . The mixture is 30 concentrated to dryness and then the product is crystallized from a methanol/ether mixture.
WO 00/75116 PCT/EP00/05783 -23 White powder, M.p. = 235 0 C, TLC (90/10 CH 2 C1 2 /MeOH containing 10%
NH
4 OH): Rf = 0.35. Analysis conforms to C1 4
H
1 8 C1NO. IR: 2995, 2700, 1675, 1600, 1440, 1395, 1210, 1090, 990, 750, 740 cm- 1 5 EXAMPLE 2 1 '-cyclopropylmethyl-3,4-Dihydro-l1-oxospiro[naphthalene-2(1H),4'-piperidine] 0 N 10 g (46.4 mmol) of 3,4-dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine] and 10 then 80 ml of DMF and 36.2 ml of THF are introduced into a three-necked flask. 6.89 g (51 mmol) of (bromomethyl)cyclopropane and 7.8 g (92.8 mmol) of NaHCO 3 are added. The suspension is brought to reflux and then maintained for 1.5 h. The solvents are evaporated at 50'C under a vacuum of less than 1 mm Hg. The residue is taken up in 200 ml of water and extracted with 3 times 100 ml of 15 ether. The ethereal phase is extracted with 100 ml of 1N HCI and then twice with 50 ml of water. The aqueous phase is basified while cold with concentrated NaOH and extracted 3 times with 100 ml of ether. The organic phase is washed with an NaCl solution and dried over Na 2
SO
4 . Once the solvent has been evaporated, 12 g of an oily residue are obtained. The hydrochloride is prepared by addition of 20 approximately 5N ethereal hydrochloric acid to a solution of the crude product in
CH
2 C1 2 . The mixture is concentrated to dryness and then the product is crystallized by addition of 20 ml of ether to a methanolic solution of the product, crystallization is allowed to take place overnight at 20-25 0 C and then the product is filtered off and washed with water. After drying, 8.4 g of product are obtained. 25 White powder, M.p. = 243 0 C, TLC (95/5 CH 2
CI
2 /MeOH containing 10%
NH
4 OH): Rf = 0.55. Analysis conforms to CI 8
H
24 CINO. N.M.R.: CDCl 3 'H ((ppm) HCl: 0.4-0.55 (m, 2H), 0.75-0.8 (min, 2H), 1.3-1.4 (m, 1H), 2.1-2.2 (min, 4H), 2.4-2.55 (min, 2H), 2.85-2.9 (m, 2H), 3.0-3.05 (min, 2H), 3.2- WO 00/75116 PCT/EP00/05783 -24 3.3 (min, 2H), 3.5-3.6 (min, 2H), 7.2-7.25 (m, 1H), 7.3-7.35 (min, 1H), 7.5-7.6 (m, 1H), 7.95-8.0 (min, 1H), 12.0-12.2 (min, 1H). IR: 2990, 2700, 1675, 1600, 1420, 1395, 1320, 1080, 980, 900, 760, 740 cm -1 5 The corresponding iodomethylate was also obtained. MP: 162 0 C EXAMPLE 3 1 '-cyclobutylmethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1 H),4'-piperidine] 0 10 The method described for Example 2, using cyclobutylmethyl bromide, results in the product in the hydrochloride form. Beige powder, M.p. = 235 0 C. TLC: (92/8 CH 2
CI
2 /MeOH containing 10% NH 4 OH): Rf = 0.7. Analysis conforms to C 19
H
26 C1NO. N.M.R.: CDCl 3 1 H ((ppm) HCl: 1.8-2.25 (min, 10H), 2.4-2.5 (m, 2H), 2.95-3.1 (m, 15 5H), 3.1-3.25 (m, 2H), 3.25-3.35 (min, 2H), 7.2-7.35 (m, 2H), 7.45-7.55 (m, 1H), 7.9-8.0 (min, 1H), 11.95-12.15 (m, 1H)) IR: 3400, 2900, 2650, 2500, 1680, 1590, 1430, 1360, 1300, 1220, 1140, 1100, 1040, 960, 930, 900, 800, 770, 740, 640 cm 20 25 EXAMPLE 4 1'-cyclohexylmethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2(1H),4'-piperidine] 0 1 ~ N - WO 00/75116 PCT/EP00/05783 -25 The method described for Example 2, using cyclohexylmethyl bromide, results in the product in the hydrochloride form. Beige powder, M.p. = 265oC. TLC: (93/7 CH 2 C1 2 /MeOH containing 10% NH 4 OH): Rf = 0.8. Analysis conforms to C 21
H
30 C1NO. 5 N.M.R.: CDCl 3 'H ((ppm) HCl: 0.95-1.3 (min, 5H), 1.6-2.1 (min, 10H), 2.5-2.65 (inm, 2H), 2.7-2.8 (min, 2H), 2.9-3.0 (min, 2H), 3.1-3.2 (min, 2H), 3.3-3.4 (min, 2H), 7.15-7.3 (min, 2H), 7.4-7.5 (min, 1H), 7.9-7.95 (min, 1H), 11.6-11.8 (m,1H)) IR: 3400, 2900, 2500, 1680, 1600, 1440, 1360, 1300, 1220, 1150, 1110, 1060, 980, 910, 760, 735 cm 10 EXAMPLE 5 1'-phenylethyl-3,4-Dihydro-l1-oxospiro[naphthalene-2(1H),4'-piperidine] 0 N The method described for Example 2, using phenethyl bromide, results in the 15 product in the hydrochloride form. Beige powder, M.p. = >275 0 C, Yd = 55%. TLC: (95/5 CH 2 C1 2 /MeOH containing 10% NH 4 OH): Rf = 0.85. Analysis conforms to C 22
H
26 C1NO. N.M.R.: CDCl 3 1H ((ppm) HCl: 2.0-2.15 (m, 4H), 2.3-2.45 (min, 2H), 2.9-3.0 (inm, 2H), 3.05-3.25 (min, 6H), 3.4-3.5 (min, 2H), 7.1-7.3 (min, 7H), 7.4-7.45 (min, 1H), 7.85 20 7.9 (min, 1H), 12.25-12.45 (min, 1H)) IR: 3400, 2900, 2500, 1670, 1600, 1450, 1360, 1290, 1220, 1110, 1010, 960, 820, 800, 740, 700 cm-1 EXAMPLE 6 25 1'-cyclopropylethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine] 0
IN
WO 00/75116 PCTIEP00/05783 -26 0.94 g (4.36 mmol) of 3,4-dihydro-1-oxospiro[naphthalene-2(1H),4'-piperidine] and then 10 ml of DMF are introduced into a three-necked flask. 1.3 g (8.7 mmol) of (bromoethyl)cyclopropane in 2 ml of DMF and then 0.73 g (8.7 mmol) of NaHCO 3 are added to the solution obtained. The suspension is brought to reflux 5 and then maintained for 1.5 h. The solvents are removed at 50'C under a vacuum of less than 1 mm Hg. The residue is taken up in 50 ml of water and extracted with three times 50 ml of ether. The ethereal phase is extracted with 100 ml of 1N HC1 and then twice with 50 ml of water. The aqueous phase is basified while cold with concentrated NaOH and extracted 3 times with 50 ml of ether. The organic phase 10 is washed with an NaCl solution and dried over Na 2
SO
4 . The solvent is removed. The oily residue is purified by fast chromatography by eluting with CH 2
C
2 enriched with methanol. 0.6 g is obtained, the hydrochloride of which is prepared by addition of approximately 5N ethereal hydrochloric acid to a solution of the crude product in CH 2 C1 2 . The mixture is concentrated to dryness and then the 15 product is crystallized by addition of 30 ml of ether to a solution of the product in 5 ml of isopropanol. Crystallization is allowed to take place for 14 h at 20-25 0 C and then the product is filtered off and washed with ether. After drying, 0.5 g of white powder is obtained, M.p. = 244 0 C, TLC: (95/5 CH 2 C12/MeOH containing 10% NH 4 OH): Rf = 0.35. Analysis 20 conforms to C 19
H
26 C1NO. N.M.R.: CDCl 3 1H ((ppm) HCl: 0.1-0.3 (m, 2H), 0.45-0.65 (m, 2H), 0.7-0.8 (m, 1H), 1.6-2.6 (m, 8H), 2.9-3.5 (min, 8H), 7.2-7.4 (m, 2H), 7.4-7.6 (t, 1H), 7.9-8.05 (d, 1H), 12.15 (1H)) IR: 2900, 2450, 1670, 1600, 1430, 1290, 1220, 950, 890, 740 cm 1 25 EXAMPLE 7 1 '-cinnamyl-3,4-Dihydro- 1-oxospiro[naphthalene-2(1H),4'-piperidine] 0 WO 00/75116 PCTIEP00/05783 -27 Prepared according to the method described in Example 2 with cinnamyl bromide, then purification by chromatography and crystallization of the hydrochloride. White powder, M.p. = 228 0 C. TLC: (95/5 CH 2 Cl 2 /MeOH containing 10% NH 4 0H): Rf = 0.55. Analysis 5 conforms to C 23
H
26 C1NO. N.M.R.: CDCl 3 1 H ((ppm) HCl: 2.0-2.25 (m, 4H), 2.3-2.5 (m, 2H), 2.9-3.85 (inm, 8H), 6.4-6.6 (min, 1H), 6.6-6.8 (d, 1H), 7.1-7.6 (min, 8H), 7.9-8.0 (d, 1H), 12.1 (1H)) IR: 2900, 2400, 1670, 1590, 1420, 1290, 1220, 970, 730, 690 cm 10 EXAMPLE 8 1'-(3,3-diphenylpropyl)-3,4-Dihydro- 1 -oxospiro[naphthalene-2(H I),4'-piperidine] 0 Prepared according to the method described in Example 6 with 3,3-diphenylpropyl bromide and preparation of the hydrochloride. A white powder is obtained, M.p. -= 15 257 0 C, TLC (95/5 CH 2 C1 2 /MeOH): Rf = 0.35. Analysis conforms to C 29
H
32 C1NO. N.M.R.: CDCl 3 1H ((ppm) HCl: 2.0-2.2 (m, 4H), 2.4-3.5 (min, 12H), 3.9-4.05 (inm, 1H), 7.2-7.4 (min, 12H), 7.4-7.6 (min, 1H), 7.9-8.0 (m, 1H), 12.3 (1H)) IR: 2900, 2350, 1670, 1590, 1450, 1300, 1220, 910, 740, 700 cm 20 EXAMPLE 9 1l'-(cyclopropylmethyl)-3,4-Dihydro-5,7-dimethyl- 1-oxospiro[naphthalene 25 2(1H),4'-piperidine] WO 00/75116 PCT/EP00/05783 -28 0
H
3
CH
3 3,4-Dihydro-5,7-dimethyl- 1 -oxospiro[naphthalene-2(1H),4'-piperidine] is pre pared according to the methods described for the synthesis of Example 1. The "N" alkylation is identical to that described in Example 6. The hydrochloride is 5 obtained in the form of a white powder, M.p. > 260 0 C. TLC: (95/5 CH 2 Cl 2 /MeOH containing 10% NH 4 OH): Rf = 0.5. Analysis conforms to C 20
H
28 CINO. N.M.R.: CDCl 3 1 H ((ppm) HCl: 0.3-0.4 (min, 2H), 0.7-0.8 (min, 2H), 1.1-1.3 (min, 1H), 2.0-2.1 (min, 4H), 2.2 (s, 3H), 2.3 (s, 3H), 2.35-2.45 (min, 2H), 2.7-2.85 (min, 4H), 10 3.0-3.2 (min, 2H), 3.4-3.5 (min, 2H), 7.15 (s, 1H), 7.6 (s, 1H), 12.15 (1H)) IR: 3400, 2900, 2500, 1670, 1605, 1470, 1430, 1280, 1180, 1020, 970, 950, 880, 830 cm -1 EXAMPLE 10 15 1l'-(cyclopropylmethyl)-3,4-Dihydro-6-methoxy-l1-oxospiro[naphthalene-2(1H),4' piperidine] O N /
H
3 C By the process of Example 9, the hydrochloride is obtained. White powder, M.p. > 255 0 C. 20 TLC (90/10 CH 2 Cl 2 /MeOH containing 10% NH 4 OH): Rf = 0.35. Analysis conforms to C 1 9
H
26 C1NO 2 . N.M.R.: CDCl 3 'H ((ppm) HCl: 0.4-0.5 (min, 2H), 0.75-0.85 (min, 2H), 1.25-1.4 (m, 1H), 2.05-2.2 (min, 4H), 2.35-2.5 (min, 2H), 2.8-2.95 (min, 2H), 2.95-3.05 (min, 2H), 3.2-3.4 (min, 2H), 3.45-3.6 (min, 2H), 3.85 (s, 3H), 6.7 (s, 1H), 6.85 (d, 1H), 7.9-8.0 25 (d, 1H), 12.15 (1H)) IR: 2900, 2420, 1660, 1590, 1430, 1250, 1220, 960, 830, 600 cm i WO 00/75116 PCT/EP00/05783 -29 EXAMPLE 11 1l'-(cyclopropylmethyl)-3,4-Dihydro-5-methoxy- 1-oxospiro[naphthalene-2(1H),4' piperidine] O \ N O 0 / 5
H
3 C Same process as for Example 10; the hydrochloride is obtained. White powder, M.p. = 244 0 C. TLC (90/10 CH 2 C1 2 /MeOH containing 10% NH 4 OH): Rf = 0.75. Analysis conforms to C 19
H
26 C1NO 2 . 10 N.M.R.: CDC1 3 1 H ((ppm) HCl: 0.4-0.5 (min, 2H), 0.75-0.85 (min, 2H), 1.25-1.4 (inm, 1H), 2.05-2.2 (min, 4H), 2.35-2.5 (min, 2H), 2.8-3.0 (min, 4H), 3.1-3.3 (min, 2H), 3.5-3.6 (min, 2H), 3.85 (s, 3H), 7.0-7.1 (min, 1H), 7.25-7.35 (min, 1H), 7.5-7.6 (min, 1H), 12.1-12.2 (1H)) IR: 2930, 2560, 2360, 1680, 1580, 1470, 1435, 1260, 1060, 970, 750 cm 1 15 EXAMPLE 12 l'-(methylcyclo-propyl)-3,4-Dihydro-7-methoxy-l1-oxospiro[naphthalene-2(1H),4' piperidine]
H
3 O 20 By using the same methods as for Example 10, the hydrochloride is obtained. White powder, M.p. = 235 0 C. TLC (90/10 CH 2 Cl 2 /MeOH containing 10% NH40H): Rf = 0.70-0.75. Analysis conforms to C 1 9
H
26 C1NO 2 . N.M.R.: CDCl 3 1H ((ppm) HCl: 0.4-0.5 (min, 2H), 0.75-0.85 (m, 2H), 1.25-1.4 (inm, 25 1H), 2.05-2.2 (min, 4H), 2.35-2.5 (min, 2H), 2.8-3.0 (min, 4H), 3.2-3.3 (m, 2H), 3.5-3.6 WO 00/75116 PCT/EP00/05783 -30 (min, 2H), 3.80 (s, 3H), 7.0-7.1 (min, 1H), 7.15-7.25 (min, 1H), 7.4 (s, 1H), 12.1-12.2 (1H)) IR: 2930, 2510, 2445, 1670, 1610, 1495, 1415, 1250, 1025 cm-1 5 EXAMPLE 13 1'-(cyclopropylmethyl)-3,4-Dihydro-7-nitro-I -oxospiro[naphthalene-2(1 H),4' piperidine] 0 I 0 N N Stage 1: 2.4 g (8.35 mmol) of ethyl 3,4-dihydro-1-oxospiro[naphthalene-2(1H),4' 10 piperidine]-l'-carboxylate, prepared according to the method described in Stage 3 of Example 1, and 35 ml of concentrated sulphuric acid are introduced into a three-necked flask. 0.79 g (12.5 mmol) of fuming nitric acid is added to the solution cooled to 0 0 C. The mixture is stirred for 1 h at 0 0 C and then for 2 h at 20-25 0 C. The solution is precipitated from 100 ml of water and ice and then 15 extracted with three times 100 ml of CH 2 C1 2 . The organic phase is washed successively with water and saturated NaCI solution. After drying over Na 2
SO
4 and evaporating the solvent, 2.75 g of an oil are obtained, which oil is chromatographed by eluting with CH 2 C1 2 gradually enriched with acetone. 1.5 g of ethyl 3,4-dihydro-7-nitro-l1-oxospiro[naphthalene-2(1H), 4'-piperidine]-1' 20 carboxylate are obtained in the form of an oily residue which crystallizes. Yd = 54%, TLC (98/2 CH 2 C1 2 /acetone): Rf = 0.3. N.M.R.: CDC1 3 1H ((ppm): 1.15 (t, 3H), 1.4 (min, 2H), 1.8-2.0 (min, 4H), 2.9-3.0 (m, 2H), 3.45-3.55 (min, 4H), 4.0-4.1 (q, 2H), 7.3 (d, 1H), 8.2 (d, 1H), 8.8 (s, 1H)) 25 Stage: 1.5 g of the product of the preceding stage is hydrolysed by the process described in Stage 4, Example 1. After chromatography by eluting with CH 2 C1 2 gradually enriched with methanol containing 10% NH 4 OH, 0.45 g is isolated. TLC (90/10 CH 2 Cl 2 /MeOH containing 10% NH4OH): Rf = 0.1.
WO 00/75116 PCTIEP00/05783 -31 Stage 3: 0.22 g (0.845 mmol) of 3,4-dihydro-7-nitro-1-oxospiro[naphthalene 2(1H),4'-piperidine] obtained in the preceding stage is suspended in 3 ml of acetonitrile. A solution of 0.343 g (2.54 mmol) of cyclopropylmethyl bromide in 0.5 ml of acetonitrile is added with stirring. The reaction mixture is brought to 5 reflux and maintained for approximately 5 h. The solvent is removed and the residue is taken up in 20 ml of CH 2 C1 2 and extracted with 20 ml of N/1 HCI. The acidic phase is basified while cold with a dilute sodium hydroxide solution to pH 12 and extracted with 3 times 20 ml of
CH
2 C1 2 . After washing, drying and removing the solvent, the residue is 10 chromatographed by eluting with CH 2 C1 2 gradually enriched with methanol containing 10% NH40H. 0.130 g of 3,4-dihydro- 1 '-(cyclopropylmethyl)-7-nitro- 1 oxospiro[naphthalene-2(1H),4'-piperidine] is obtained. TLC (90/10
CH
2 C1 2 /MeOH containing 10% NH 4 OH): Rf = 0.7. The hydrochloride is prepared as described above. White powder, M.p. = 256 0 C. 15 TLC (90/10 CH 2 C1 2 /MeOH containing 10% NH4OH): Rf = 0.7. Analysis conforms to C 1 8
H
23 C1N 2 0 3 . N.M.R.: CDCl 3 1H ((ppm) HCl: 0.4-0.5 (min, 2H), 0.7-0.8 (min, 2H), 1.2-1.4 (min, 1H), 2-2.25 (min, 4H), 2.4-2.6 (min, 2H), 2.8-2.9 (min, 2H), 3.05-3.3 (min, 4H), 4.5-4.6 (inm, 2H), 7.45 (d, 1H), 8.3 (d, 1H), 8.8 (s, 1H), 12.1 (1H)) 20 IR: 2940, 2500, 2440, 1690, 1610, 1520, 1410, 1345, 1220, 1105,960 cm 25 EXAMPLE 14 l'-(cyclopropylmethyl)-7-Amino-3,4-dihydro-l1-oxospiro[naphthalene-2(1H),4' piperidine] 0
H
2 30 WO 00/75116 PCT/EP00/05783 -32 60 mg (0.19 mmol) of 3,4-dihydro-1'-(methylcyclo-propyl)-7-nitro-1 oxospiro[naphthalene-2(1H),4'-piperidine], obtained as described in Example 13, are dissolved in 1 ml of THF and then, with stirring, 0.21 g of tin chloride hydrate is introduced. The solution is brought to reflux for 1 h. The reaction liquors are 5 charged to a saturated NaHCO 3 solution and extracted with 3 times CH 2 C1 2 . The organic phase is washed and dried over Na 2
SO
4 . The solvent is evaporated and the residue obtained is chromatographed by eluting with CH 2 C1 2 gradually enriched with methanol containing 10% NH 4 OH. 29 mg of product are obtained. N.M.R.: CDCl 3 'H ((ppm): 0.1-0.2 (min, 2H), 0.4-0.55 (min, 2H), 0.85-1.0 (min, 1H), 10 1.6-1.7 (min, 2H), 1.9-2.1 (min, 4H), 2.3-2.4 (min, 2H), 2.5-2.75 (min, 4H), 2.8-2.9 (inm, 2H), 3.6-3.8 (2H), 6.8 (d, 1H), 7.0 (d, 1H), 7.2 (s, 1H)) The hydrochloride is crystallized from ether. 26 mg of a yellow powder are obtained. M.p. = 200 0 C, decomposition. TLC (95/5 CH 2 Cl 2 /MeOH containing 10% 15 NH 4 OH): Rf = 0.45. EXAMPLE 15 1'-(cyclopropylmethyl)-7-Chloro-3,4-dihydro-l1-oxospiro[naphthalene-2(1H),4' piperidine] 20 Stage 1: Piperidine-1,4-dicarboxylic acid, 4-ethyl 1-t-butyl diester. 60 g (0.381 mol) of ethyl isonipecotate and 400 ml of THF are placed in a three necked flask which is protected from moisture and which is under an inert atmosphere, and 18.3 g (0.458 mol) of sodium hydroxide pellets are added. A 25 solution of 100 g (0.458 mol) of di-t-butyl dicarbonate in 170 ml of THF is added over 1 h with stirring to the suspension. The temperature reaches 45 0 C. The reaction mixture is left stirring for 14 h at 20-25 0 C and is then poured onto 2 1 of water and ice and extracted with 3 times 500 ml of ether. The organic phase is washed with 3 times 250 ml of a saturated NaCl solution, dried over Na 2
SO
4 and 30 concentrated. The residue is chromatographed by eluting with CH 2 C1 2 gradually WO 00/75116 PCT/EP00/05783 -33 enriched with acetone and then distilled under a vacuum of 0.09 mm Hg and at a vapour temperature of 95-102oC. 82 g are obtained (Yd = 83.6%). TLC (95/5
CH
2 C1 2 /acetone): Rf= 0.60. N.M.R.: CDC1 3 1 H ((ppm): 1.2-1.3 (t, 3H), 1.4 (s, 9H), 1.5-1.6 (m, 2H), 1.8-1.9 5 (in, 2H), 2.35-2.45 (min, 1H), 2.7-2.85 (m, 2H), 3.9-4.0 (min, 2H), 4.05-4.15 (q, 2H)) Stage 2: 4-(4-Chlorophenethyl)piperidine-1,4-dicarboxylic acid, 4-ethyl 1-t-butyl diester 6.16 g (60.9 mmol) of diisopropylamine and 174 ml of THF, dried over molecular 10 sieve, are introduced, by transfer under nitrogen, into a three-necked flask which is protected from moisture and which is under an inert atmosphere. The solution is cooled to -10 0 C and 24.3 ml of 2.5N n-butyllithium in hexane (60.9 mmol) are run in. The mixture is stirred for 15 min at -10 0 C and cooled to -70'C, and a solution of 10.4 g (40.6 mmol) of the product from the preceding Stage 1 in 86 ml of THF 15 is run in over approximately 20 min. The mixture is stirred for 10 min at -70 0 C and then 10.9 g (60.9 mmol) of HMPT are added. The mixture is kept stirring at -70 0 C for 1.5 h and a solution of 4-chlorophenethyl bromide (10.7 g, 48.7 mmol) in 86 ml of THF is run in over 20 min at -70 0 C. The mixture is stirred at 20-25 0 C for 14 h and then poured over 350 ml of water and extracted 3 times with ether. 20 The organic phase is washed with an N/1 HCI solution and then with a saturated NaCl solution. After drying and concentrating, 17 g of an orange oil are obtained, which oil is chromatographed by eluting with CH 2 C1 2 gradually enriched with hexane, and then with acetone. 11.8 g are obtained (Yd = 80%). TLC (95/5 CH 2 C1 2 /acetone): Rf= 0.70. 25 NMR: CDCl 3 1H ((ppm): 1.2-1.3 (t, 3H), 1.4 (s, 9H), 1.3-1.4 (m, 2H), 1.7-1.8 (m, 2H), 2.0-2.1 (min, 2H), 2.3-2.4 (min, 2H), 2.7-2.9 (min, 2H), 3.7-3.9 (min, 2H), 4.05-4.15 (q, 2H), 6.9-7.0 (m, 2H), 7.1-7.2 (min, 2H)) Stage 3: Ethyl 4-(4-chlorophenethyl)piperidine-4-carboxylate 10.8 g of the product from the preceding Stage 2 and 50 ml of CH 2
C
2 are 30 introduced into a three-necked flask which is protected from moisture. The solution is stirred and 25 ml of trifluoroacetic acid are added at 20-25 0 C. The mixture is kept stirring for 30 min and then concentrated to dryness and the WO 00/75116 PCTIEP00/05783 -34 residue is taken up in ether. The organic phase is washed with a 10% sodium hydroxide solution and then with a saturated NaCl solution. After drying and concentrating, 9 g of an oil are obtained, which oil crystallizes. TLC (90/10 CH 2 C1 2 /MeOH containing 10% NH 4 0H): Rf = 0.45. 5 NMR: CDCl 3 1H ((ppm): 1.1-1.25 (t, 3H), 1.3-1.4 (m, 2H), 1.7-1.8 (m, 2H), 2.1-2.2 (m, 2H), 2.35-2.45 (m, 2H), 2.6-2.7 (m, 2H), 2.9-3.0 (m, 2H), 3.3 (1H), 4.1-4.2 (q, 2H), 6.9-7.0 (dd, 2H), 7.1-7.2 (dd, 2H)) Stage 4: Ethyl 1 -(cyclopropylmethyl)-4-(4-chlorophenethyl)piperidine-4 10 carboxylate 3.4 g (11.5 mmol) of the product from the preceding Stage 3, 85 ml of THF, dried over molecular sieve, and then, with stirring, 14.9 ml of triethylamine and 2.4 ml (20.9 mmol) of 85% (bromomethyl)cyclopropane are successively introduced into a round-bottomed flask which is protected from moisture and which is under 15 nitrogen. The mixture is brought to reflux for 14 h and then concentrated to dryness, and the residue is taken up in water and extracted twice with ether. The organic phase, washed with a saturated NaCl solution and dried, is concentrated. 3 g of crude product are obtained, which product is chromatographed (eluent:
CH
2
C
2 gradually enriched with methanol containing 10% NH 4 OH). 2.6 g of oily 20 product are obtained. Yd = 65%. TLC (95/5 CH 2 C1 2 /MeOH containing 10% NH 4 OH): Rf= 0.50. N.M.R.: CDCl 3 'H ((ppm): 0.0-0.1 (min, 2H), 0.35-0.45 (m, 2H), 0.7-0.8 (min, 1H), 1.1-1.2 (t, 3H), 1.4-1.5 (m, 2H), 1.7-1.8 (min, 2H), 1.9-2.1 (m, 2H), 2.1-2.2 (min, 2H), 2.3-2.4 (m, 2H), 2.7-2.85 (min, 2H), 4.1-4.2 (q, 2H), 6.9-7.0 (dd, 2H), 7.1-7.2 (dd, 25 2H)) Stage 5: 1-(Cyclopropylmethyl)-4-(4-chlorophenethyl)-piperidine-4-carboxylic acid 2.2 g (6.28 mmol) of the preceding ester and 6.6 ml of anhydrous dimethyl 30 sulphoxide are introduced into a round-bottomed flask which is protected from moisture and which is under nitrogen. A solution of potassium t-butoxide (4.4 g, 39 mmol) in 30 ml of dimethyl sulphoxide is added with stirring. The mixture is WO 00/75116 PCTIEP00/05783 -35 left stirring for 2 h at 20-25oC. The reaction mixture is charged to 200 ml of water and then washed with ether. The aqueous phase is acidified to pH 5-7 with 10% HC1. The precipitate is filtered off and washed with water. The acid obtained is crystallized from a CH 2
CI
2 /methanol mixture. M.p. = 250 0 C. 5 NMR: CDCl 3 1 H ((ppm): 0.2-0.3 (m, 2H), 0.5-0.6 (m, 2H), 1.07-1.1 (m, 1H), 1.6-1.9 (m, 4H), 2.25-2.35 (m, 2H), 2.5-2.6 (m, 2H), 2.65-2.75 (m, 2H), 2.8-2.9 (m, 2H), 3.3-3.4 (m, 2H), 6.9-7.0 (dd, 2H), 7.1-7.2 (dd, 2H)) IR: 3370, 1490, 1445, 1380, 1240, 1170, 1095, 965, 805 cm -1. 10 Stage 6: 7-Chloro-3,4-dihydro- 1 '-(cyclopropylmethyl)- 1 oxospiro[naphthalene-2(1 H),4'-piperidine]. 0.3 g (0.9 mmol) of the acid obtained previously and 6 ml of benzene are introduced into a round-bottomed flask which is protected from moisture and which is under nitrogen. 0.24 g of PC 5 ls and 6 ml of CH 2 C1 2 are added, followed by 15 a further 0.24 g of PC 5 ls. The mixture is stirred for 2 h at 20-25oC. The mixture is cooled to 0 0 C, 0.44 ml of tin tetrachloride is introduced (copious precipitation), 12 ml of CH 2 C1 2 are added and the mixture is maintained at 0 0 C for 1 h and then at 20-25 0 C for 14 h. The solvents are removed and the residue is taken up in water. The aqueous phase is washed with ether and then basified to pH 12 with 20 NaOH and extracted with ether. The organic phase is washed, dried and concentrated. The crude product is chromatographed by eluting with CH 2 Cl 2 gradually enriched with methanol containing 10% NH 4 OH. 22 mg of product are obtained, which product is treated in solution in CH 2 C1 2 with 5N ethereal hydrochloric acid. After crystallization from ethyl acetate, the product is filtered 25 off and dried at 50'C under vacuum. White powder. TLC (90/10 CH 2 Cl 2 /MeOH containing 10% NH 4 OH): Rf = 0.55. M.p. = 263 0 C. N.M.R.: CDCl 3 1 H ((ppm) HCl: 0.4-0.5 (min, 2H), 0.7-0.8 (m, 2H), 1.2-1.3 (min, 1H), 2.0-2.15 (min, 4H), 2.4-2.55 (m, 2H), 2.8-2.9 (m, 2H), 2.95-3.05 (m, 2H), 3.1-3.3 30 (min, 2H), 3.5-3.6 (min, 2H), 7.2-7.3 (m, 1H), 7.4-7.5 (m, 1H), 7.9 (s, 1H), 12.2 (1H)) IR: 2930, 2440, 1720, 1490, 1230, 1185, 1095, 1025, 810 cm -1.
WO 00/75116 PCT/EP00/05783 -36 EXAMPLES 16-34 Following the general procedures described above, the following additional compounds listed in table 1 were prepared. 5 Table 1 Example R 1
R
2
R
3
R
4 A R 16 =0 H H CH 2
CH
3 17 =0 H H CH 2
CH
2
CH=CH
2 18 =0 H H CH 2 H CH3 19 =0 H H CH 2 20 =0 H H CH 2
CH
2 10 Table 1 (cont.) Example R R 2 R R4 A R 21 =0 H H CH 2
CH
22 =0 H H CH 2 CH 23 H OH H H CH 2
CH
2
-<
WO 00/75116 PCT/EP00/05783 -37 24 H H H H CH2 CH2 25 =0 H H Bond CH 2 26 =0 H H CH 2
CH
2
CH
2 27 =0 H H CH CH2
CH
3 28 =0 6-Cl H CH2 CH2 29 =0 6-F H CH 2
CH
2 30 =0 6:OCH 3 7:OCH 3
CH
2 CH2 31 =0 H H CH 2 32 =0 H H CH2 33 =0 H H CH2 34 =0 6:OCH3 H CH2 MP and NMR data for the compounds of examples 16 to 34 are provided below: 5 Example 16 MP = 240-243oC R.M.N. CDCl 3 'H 6 ( ppm) Base:l,5-1,6 ( m,2H ); 1,95-2,05 (m,4H ); 2,25 ( s,3H ); 2,3-2,4 (m,2H); 2,45-2,55 (m,2H ); 2,9-2,95 (m,2H); 7,1-7,15 (m,1H ); 7,2 7,25(m,lH); 7,35-7,4 (m,IH); 7,9-7.95 (m,lH) 10 Example 17 MP = 242-244 0
C
WO 00/75116 PCT/EP00/05783 -38 R.M.N. CDC1 3 'H 8 (ppm ) HC1:2,05-2,15 (m,4H); 2,3-2,45 (m,2H); 3,0-3,1 (m,2H); 3,1-3,25 (m,2H); 3,35-3,5 (m,2H ); 3,55-3,6 (m,2H); 5,4-5,55 (m,2H ); 6,1 -6,25( m,1H ); 7,2-7,35 (m,2H ); 7,45-7.5 (m,1H ); 7,9-7,95 (m,lH ); 12,3 12,45 (m,lH ) 5 Example 18 MP = 244-245 0 C R.M.N. CDC1 3 'H 8 ( ppm ) HCI: 1,15 ( d,6H ); 2,0-2,1 (m,4H ); 2,15-2,3 (m, 1H ); 2,55-2,65 (m,2H); 2,75-2,8 (m,2H); 2,95-3,0 (m,2H); 3,1-3,25 (m,2H); 10 3,35-3,45 (m,2H);7,2-7,35 (m,2H); 7,45-7.5 (m,1H ); 7,9-7,95 (m,IH ); 11,7 11,8 (m,1H) Example 19 MP = 95-97 0 C 15 R.M.N. CDC1 3 1H 8 (ppm ) base: 0,6-0,7 (m,2H); 0,8-0,95 (m,2H); 1,4-1,5 (m,2H); 1,6-1,7 (m,1 H ); 1,8-2,1 ( m,4H ); 2,9-3,5 (m,2H ); 3,4-3,8 (m,4H); 7,1 7,3 (m,2H); 7,35-7.45 (m,H ); 7,9-8,0 ( m,1H ); Example 20 20 MP = 220-221 0 C R.M.N. CDC1 3 '1H 8 ( ppm ) HCI: 1,05-1,3 (m,2H); 1,5-1,9 (m,1 H ); 2,0-2,2 (m,SH); 2,3-2,55 (m,2H); 2,9-3,4 (m,6H); 3,4-3,6 (m,2H); 7,0-7,6 ( m,8H); 7,9-8,1 (m,1 H ); 12,2-12,4 (m,1H) 25 Example 21 MP = 261-262 0 C R.M.N. CDC1 3 'H 6 ( ppm ) HCI: 2,0-2,1 (m,4H ); 2,4-2,5 (m,2H); 2,95-3,05 (m,2H); 3,1-3,25 (m,2H); 3,3-3,4 (m,2H); 4,1-4,15 (m,2H); 7,2-7,35 (m,2H); 7,4-7,5 (m,4H); 7,65-7,7 (m,2H); 7,9-7,95 (m, 1H); 12,25-12,5 (m,1H) 30 Example 22 WO 00/75116 PCT/EP00/05783 -39 MP = > 250 0 C R.M.N. CDC1 3 1 H 8 ( ppm ) base: 1,4-1,55 (m,2H); 1,9-2,05( m,4H ); 2,2-2,35 (m,2H); 2,4-2,55 (m,2H ); 2,8-2,95 (m,2H ); 4,2 (s,1 H ); 6,8-7,0 ( m,4H ); 7,15 ( d,1H); 7,2-7,35 (m,5H); 7,4 (t,IH); 7,9 (d ,1H) 5 Example 23 MP = 91-93 0 C R.M.N. CDCI 3 1H 8 ( ppm ) base: -0,05-0,05 (m,2H); 0,35-0,45( m,2H ); 0,7-0,85 (m,1 H ); 1,25-1,85 (m,7H ); 2,2 (d,2H ); 2,2-2,4 (m,2H ); 2,5-2,6 ( m,1 H ); 2,6-2,7 10 ( m,3H ); 4,2 (s,1 H ); 7,0- 7,3 (m ,4H) Example 24 MP = 256-258 0 C R.M.N. CDC1 3 1 H 8 (ppm ) base: 0,0-0,1 (m,2H); 0,4-0,5( m,2H); 0,75-0,85 15 (m,1H ); 1,45-1,55 (m,4H); 1,6-1,65 (m,2H); 2,2 (d,2H); 2,35-2,6 (m,6H); 2,7 2,8 ( m,2H ); 6,9- 7,05 (m ,4H) Example 25 MP= 241 0 C 20 R.M.N. CDC1 3 1 H 8 (ppm) HCI: 0,0-0,15 (m,2H); 0,4-0,55 (m,2H); 0,75-0,9 (m,1 H ); 1,35 (d,2H); 1,9-2,15 (m,4H); 2,25 (d,2H); 2,9 ( s,2H ); 3,0 (d,2H); 7,25 (t, 1H); 7,35 (d 1H); 7,5 (t, 1H); 7,65 (d, 1H); 12,1-12,2 ( 1H) Example 26 25 MP = 242-243 0 C R.M.N. CDC1 3 'H 8 ( ppm ) HCl: 0,4-0,5 (m,2H); 0,7-0,8 ( m,2H); 1,2-1,35 (m,1H); 1,85-2,0 (m,4H); 2,2-2,3 (m,2H); 2,3-2,4 (m,2H); 2,7-2,9 (m,6H); 3,4 3,5 (m,2H); 7,15-7,4 (m,4H);12,1-12,3 (1H) 30 Example 27 MP = 234 0
C
WO 00/75116 PCT/EP00/05783 -40 R.M.N. CDCl 3 'H 8 (ppm ) HCI: 0,45 (m,2H ); 0,75 ( m,2H); 1,35 (m,1 H ); 1,4( dd,3H ); 1,85 (m,2H); 2,1 (m,3H ); 2,3 ( m,1H ); 2,75 (m,2H); 2,9 (m, 2H) 3,25 (m,1H); 3,45-3,8 (m,3H); 7,3-7,45 (m,2H);7,6 (m,1H); 8,0 (dd,1H); 12,1 (1H) 5 Example 28 MP = > 250 0 C R.M.N. CDC1 3 'H 8 (ppm ) HC1: 0,4-0,5 (m,2H); 0,75-0,85 (m,2H ); 1,3-1,4 (m,IH ); 2,1-2,2 (m,4H); 2,4-2,55 (m,2H ); 2,9-2,95 (m,2H); 3,0-3,05 (m, 2H); 3,2-3,3 (m,2H); 3,5-3,6 (m,2H); 7,25-7,3 (m,2H);7,9,7,95 (m,1H); 12,2 (1H) 10 Example 29 MP = 227'C R.M.N. CDC1 3 'H 8 (ppm) HCl: 0,4-0,5 (m,2H); 0,75-0,85 (m,2H ); 1,3-1,4 (m,1H ); 2,0-2,2 (m,4H); 2,4-2,6 (m,2H ); 2,85-2,95 (m,2H); 3,0-3,1 (m, 2H); 15 3,2-3,3 (m,2H); 3,5-3,6 (m,2H); 6,9-7,0 (m,1H ); 7,0-7,1 (m,1H ); 7,95-8,05 (m,1H); 12,1 (1H) Example 30 MP = 229 0 C 20 R.M.N. CDC1 3 'H 8 ( ppm ) HCl: 0,45 (m,2H); 0,75 ( m,2H ); 1,35 (m,1H ); 2,15 (m,4H); 2,45 ( td,2H ); 2,9 (m,2H); 2,95 (m, 2H ); 3,3 (m,2H); 3,55 (m,2H); 4,85 (s,3H); 4,95 (s,3H); 6,65 (s,1H); 7,45 (s,1H); 12,05 (1H) Example 31 25 MP = 189-192 0 C R.M.N. CDC1 3 'H 5 ( ppm ) HCI: 0,2-0,3 (m,1 H ); 0,6-0,7 ( m,1 H ); 0,7-0,8 (m,1H); 0,8-0,9 (m,IH); 1,1-1,2 (m,IH); 1,55 (d,3H); 1,6-1,7 (m,1H); 2,1-2,2 (m,4H); 2,5-2,7 (m,2H); 3,0-3,1 (m,2H); 3,3-3,6 (m,4H); 7,2-7,25 (m,IH); 7,3 7,35 (m,1H); 7,45-7,5 (mlH); 8,0-8,05 (m,1H); 11,85 (1H) 30 Example 32 WO 00/75116 PCTIEP00/05783 -41 MP = > 235 0 C R.M.N. CDC1 3 'H 8 (ppm) HCI: 1,7 (d,3H); 2,1-2,2 (m,4H); 2,4-2,5 (m,2H); 2,6-2,7 (m,2H); 2,9-3,1 (m,4H); 3,2-3,3 (m,2H); 3,4-3,5 (m,2H); 5,3-5,4 (m,1H );5,6-5,7 (m,1H); 7,2-7,3 (m,1H); 7,3-7,35 (m,1H); 7,5-7,6 (mlH); 7,95-8,0 5 (m,1H); 12,2 (1H) Example 33 MP = 209 0 C R.M.N. CDCl 3 'H 8 (ppm ) HCI: 2,1 (m,4H); 2,25 (m,2H); 2,45 (m,2H); 2,7 10 (m,2H); 2,9 ( m, 2H); 3,0 (m,2H); 3,15 (m,2H); 3,4 (m,2H); 7,1-7,35 (m,7H); 7,5 (m,1H ); 7,95 (m,1H ); 11,95 (1H) Example 34 MP = 228 0 C 15 R.M.N. CDCl 3 1H 8 (ppm ) HCl: 2,0-2,2 (m,4H); 2,4 ( td,2H); 3,0 (m,2H); 3,3 ( qd, 2H ); 3,45 (m,2H); 3,75 (t,2H); 3,85 (s,3H ); 6,55 (qt,1 H ); 6,7 (m,2H); 6,85 (dd,1H); 7,35 (m,3H); 7,45 (d,2H); 7,95 (d,1H); 11,95 (1H). 20 EXAMPLES 35-69 Following procedures known in the art, some of the tetralones described above were alkylated to yield the following additional compounds listed in table 2. Table 2 Ex. R'-R 2
R
3 R4 Rs A Rf 35 =0 5:OCH 3 H (CH 2
)
2 -c-C 3
H
5
CH
2 0.7 36 =0 5:OCH 3 H CH 2 -c-C 4 H7, CH 2 0.5 37 =0 5:OCH 3 H CH 2 -c-C 6 Hl CH 2 0.8 38 =0O 5:OCH 3 H CH 2
-CH=CH-C
6
H
6
CH
2 0.7 39 =0 5:OCH 3 H CH 2
-CH
2
-C
6
H
6
CH
2 0.7 WO 00/75116 PCTIEPOO/05783 -42 40 =0 5:OCH 3 H CH 2
-CH
2
-CH
2
-C
6
H
6
CH
2 0.55 41 =0 5:OCH 3 H (CH 2
)
2
-CH-(C
6
H
6
)
2
CH
2 0.90 42 =0 6:OCH 3 H (CH 2
)
2 -c-C 3
H
5
CH
2 0.4 43 =0 6:OCH 3 H CH 2
-C-C
4
H
7
CH
2 0.3 44 =0 6:OCH 3 H CH 2
-C-C
6
H
11
CH
2 0.55 45 =0 6:OCH 3 H CH 2
-CH=CH-C
6
H
6
CH
2 0.5 46 =0 6:OCH 3 H CH 2
-CH
2
-C
6
H
6
CH
2 0.5 47 =0 6:OCH 3 H CH 2
-CH
2
-CH
2
-C
6
H
6
CH
2 0.4 48 =0 6:OCH 3 H (CH 2
)
2
-CH-(C
6
H
6
)
2
CH
2 0.7 49 =0 7:OCH 3 H (CH 2
)
2
-C-C
3
H
5
CH
2 0.5 50 =0 7:OCH 3 H CH 2
-C-C
4
H
7
CH
2 0.2 51 =0 7:OCH 3 H CH 2
-C-C
6 Hii CH 2 0.4 52 =0 7:OCH 3 H CH 2
-CH=CH-C
6
H
6
CH
2 0.4 53 =0 7:OCH 3 H CH 2
-CH
2
-C
6
H
6
CH
2 0.4 54 =0 7:OCH 3 H CH 2
-CH
2
-CH
2
-C
6
H
6
CH
2 0.3 55 =0 7:OCH 3 H (CH 2
)
2
-CH-(C
6
H
6
)
2
CH
2 0.65 Table 2 (cont.) Ex. R'-R 2 3 R R 5 A Rf 56 =0 H H (CH 2
)
2
-C-C
3
H
5
CHCH
3 0.4 57 =0 H H CH 2
-C-C
4
H
7
CHCH
3 0.2 58 =0 H H CH 2
-C-C
6
H
11
CHCH
3 0.5 59 =0 H H CH 2
-CH=CH-C
6
H
6
CHCH
3 0.45 60 =0 H H CH 2
-CH
2
-C
6
H
6
CHCH
3 0.5 61 =0 H H CH 2
-CH
2
-CH
2
-C
6
H
6
CHCH
3 0.4 62 =0 H H (CH 2
)
2
-CH-(C
6
H
6
)
2
CHCH
3 0.7 63 =0 6:Cl H (CH 2
)
2
-C-C
3
H
5
CH
2 0.5 WO 00/75116 PCT/EP00/05783 -43 64 =0 6:C1 H CH 2 -c-C 4
H
7
CH
2 0.3 65 =0 6:C1 H CH 2 -c-C 6 Hii CH 2 0.65 66 =0 6:Cl H CH 2
-CH=CH-C
6
H
6
CH
2 0.55 67 =0 6:Cl H CH 2
-CH
2
-C
6
H
6
CH
2 0.65 68 =0 6:Cl H CH 2
-CH
2
-CH
2
-C
6
H
6
CH
2 0.5 69 =0 6:Cl H (CH 2
)
2
-CH-(C
6
H
6
)
2
CH
2 0.85 EXAMPLE 70 3,4-Dihydro-6-methoxy-1 -oxospiro[naphthalene-2(1 H),4'-piperidine] O NH /
H
3 C 5 The synthesis is similar to the one described in example 1 except in stage 3 wherein 6-methoxytetralone is used instead of 1-tetralone. N.M.R.: CDCl 3 'H ((ppm) Base: 1.9-2.3 (min, 6H); 2.9-3.1 (min, 2H); 3.3-3.6 (inm, 4H); 3.85 (s, 3H); 6.65 (s, 1H); 6.8-6.9 (min, 1H); 7.9-8.0 (dd, 1H); 9.5 (bs, 2H)). 10 M.P. = 236-237 0 C, TLC (90/10 CH 2 C1 2 /MeOH containing 10% NH4OH): Rf = 0.25. IR: 2724, 1657, 1595, 1446, 1258, 1223, 1086, 978, 906, 839 cm 1 As noted above, the invention compounds of Formula I are useful for 15 treating chronic pain and other CNS disorders such as seizures, e.g. epilepsy. The compounds have been evaluated in standard assays to measure their ability to block isolated mammalian Na neuronal channels, as well as their ability to antagonize prostaglandin E 2
(PGE
2 ) production. Both assays are routinely utilized to indicate clinical utility of compounds for treating chronic pain and other CNS 20 disorders (see Tonelian et al., Anesthesiology, 24: 949-951, 1991).
WO 00/75116 PCT/EP00/05783 -44 EXAMPLE 71 Sodium channel [3H] batrachotoxin (BTX) binding assay Cerebral cortices from male Sprague-Dawley rats were homogenized in a glass 5 Teflon homogenizer in 10 volumes of ice-cold 0.32 M sucrose, 5 mM K 2
HPO
4 (pH 7.4 at 4 0 C). The homogenate was centrifuged at 1000 g. for 10 min, the pellet was resuspended in the same volume of sucrose and recentrifuged. The pellet was discarded and the two supernatants resulting from these two centrifugations were pooled and centrifuged at 20000 g. for 10 min. The resulting pellet was 10 resuspended in a Na-free assay buffer containing 50 mM HEPES, 5.4 mM KC1, 0.8 mM MgSO 4 , 5.5 mM glucose and 130 mM choline chloride (pH 7.4 at 25 0 C). Binding assay were initiated by the addition of 150-200 ptg synaptosomal protein to an assay buffer containing 25 pg scorpion venom (Leirus quinquestriatus), 0.1% BSA and 10 nM [3H] batrachotoxin (40 Ci/mmol, NEN) in the presence or 15 absence of different concentrations of unabelled drugs (250 gl final volume). Non specific binding was determined in the presence of 0.3 mM veratridine. Reactions were incubated for 90 min at 25 0 C and bound ligand was separated from free by vacuum filtration through Whatman GF/B filters; the filters were washed with 2x5 ml buffer (5 mM HEPES, 1.8 mM CaCI 2 , 0.8 mM MgSO4, 130 mM choline 20 chloride, 0.01% BSA ; pH 7.4 at 25 0 C) and bound ligand was estimated by liquid scintillation spectrometry. EXAMPLE 72 25 22 Na + influx into SK-N-SH neuroblastoma cells Characterization of Na + channels activity is performed using human SK-N-SH cells in 96-well culture plates. The effect of tested compounds on Na + influx through the Na channels is evaluated under stimulation by veratridine.
WO 00/75116 PCT/EP00/05783 -45 SK-N-SH cells are preincubated for 15 min at 37 0 C in the presence of test compounds in a 25 mM hepes/Tris pH 7.5 buffer containing 5.4 mM KC1, 0.8 mM MgSO 4 , 1.8 mM CaC1 2 , 5mM glucose, 0.1% BSA, 140 mM choline chloride. The influx of Na + is induced by the incubation for 10 min at 37 0 C of SK-N-SH 5 cells in the presence of test compound and veratridine in the incubation buffer supplemented with 1 pM ouabaine, 10 mM NaC1, 130 mM choline chloride and 2 2 Na + (Jacques, Y, Fosset, M. and Lazdunski, M., (1978), Molecular properties of the action potential Na+ ionophore in neuroblastoma cells. J. Biol. Chem., 253, 7383-7392). 10 Following this 22 Na+ uptake, cells are washed with 0.1 mM MgCl 2 . The radioactivity is then measured with a microplate reader (Topcount, Packard) after the addition of a scintillation liquid (Microscint 40, Packard). The reference compound is tetrodotoxin tested at 7 concentrations ranging from 10-1oM to 10 -7 M in order to determine an IC 5 0 value. 15 EXAMPLE 73 Analgesic activity on chronic hyperalgesia induced by PGE 2 in rats The test consists in determining the analgesic effect of the test compound in rats 20 by the Randall and Selitto test, in which chronic hyperalgesia has been triggered by intraplantar injection of PGE 2 over 4 days into a leg, according to a protocol adapted from Nakamura-Craig et al (Pain, 63: 33-37, 1995). The study is carried out on batches of 120-140 g Sprague-Dawley rats to which 100 ng of PGE 2 is administered in a volume of 100 gl by the intraplantar route, 25 for 4 consecutive days twice a day; this causes chronic hyperalgesia in the leg from the 5th day, for at least one week. On the day of the test, in the morning, the threshold of reaction to pain is checked by the Randall and Selitto test, and animals whose threshold is y100 arbitrarily defined units are selected. In the afternoon, the measurement is repeated after prior administration by the s.c. route 30 of a solution of the test compound; this administration is carried out 30 min before measuring the pain threshold. For each batch, the analgesic activity (%) is WO 00/75116 PCTIEP00/05783 -46 calculated from the means of the thresholds measured before and after treatment, as compared with that of the control animals, who received only the vehicle. The following Table 3 lists the Na channel binding and the analgesic activities of representative compounds of the invention when measured in the 5 foregoing assays. Table 3: Pharmacological activities Compound of [3H] BTX assay: 22 Na influx PGE 2 assay: Na + channel binding Analgesic activity at Example No Ki (nM) IC50 (pM) 10 mg/kg S.C. (%) 2 876 10.7 49 6 1435 3.4 67 7 366 0.94 57 8 397 0.97 47 10 3890 30 100 33 291 1.2 81 36 475 3.4 51 42 ND 4.3 46 43 ND 6 39 47 ND 0.6 66 49 2183 7.6 38 70 ND ND 46 The foregoing biological data establish that the compounds of Formula I 10 are particularly useful for treating CNS disorders in mammals, especially neuropathic pain, trigeminal neuralgia, diabetic neuropathy, sciatic neuropathy and seizures. The compounds are particularly well suited to the treatment of diabetic neuropathy, which is the most common complication accompanying diabetes mellitus. The compounds also are useful for prophylaxis and treatment of 15 migraine.
WO 00/75116 PCT/EP00/05783 -47 The invention compounds can be administered to humans who are in need of treatment for a chronic pain condition or seizure disorder by both the oral and parenteral routes, for instance as tablets or capsules, or as subcutaneous or intravenous injections. The compounds will be administered in an amount which 5 is effective to control and treat the seizure disorder or relieve the neuropathic pain sensation. Such effective amounts will generally be from about 0.1 to about 2000 mg/kg of mammalian body weight. Commonly prescribed doses will be from about 5 mg/kg to about 500 mg/kg. Such dosage amounts can be administered to adult humans from 1 to 4 times a day for the relief of neuropathic pain and seizure 10 disorders. The precise dose to be employed will depend upon the specific compound of Formula I utilized, the particular condition of the subject being treated, and generally will be dictated by the attending physician or other medical practitioner. The compounds can be formulated by normal methods for convenient oral 15 or parenteral dosing. Typical oral forms are tablets, capsules, troches, elixirs, syrups, suspensions, and controlled sustained release forms, for example through osmotic pumps. The compounds can likewise be formulated for administration intraperitoneally, subcutaneously, intramuscularly, transdermally, sublingually or intravenously. The compounds are formulated by using conventional diluents, 20 excipients, carriers and binders routinely used in the phamaceutical art. For example, the compounds can be admixed with carriers, diluents and excipients such as starch, cellulose, PVP, methylcellulose, sugar, wax, talc, and with stabilizers and binders such as Mg stearate, MgO, CaCO 3 , methyl-p hydroxybenzoate (methylparaben), and n-propyl-p-hydrobenzoate 25 (propylparaben). The following additional examples illustrate typical pharmaceutical formulations which are provided by this invention.
WO 00/75116 PCT/EP00/05783 -48 EXAMPLE 74 Tablet Preparation 5 Compound of Example 10 25.0 mg Microcrystalline cellulose 50.0 mg Modified food corn starch 50.0 mg Magnesium stearate 1.0 mg The above ingredients are blended to uniformity and compressed into a tablet. 10 Such tablets are administered at the rate of 1 to 4 times a day to a human suffering from chronic pain. EXAMPLE 75 Intravenous Preparation 15 Compound of example 2 400 mg Acetate buffer 20 ml dil aqueous HCI or NaOH to pH6.5 Sterile isotonic saline qs 1000 ml The invention compound is dissolved in the acetate buffer and the pH is adjusted 20 to 6.5. Isotonic saline is added to a volume of 1000 ml. The solution is filled into a sterile flexible plastic container equipped with a drip tube. The solution is administered IV to a patient suffering from diabetic neuropathy.

Claims (13)

1. A tricyclic compound of Formula I: R 1 R 2 R3 N-- R 5 R 4 (i) 5 wherein: R1 is hydrogen or hydroxy; R 2 is hydrogen or hydroxy; or R 1 and R 2 together are oxygen; A is a bond, CH 2 , CH CH 3 , CH 2 CH 2 or C(CH 3 ) 2 ; 10 R 3 and R 4 are the same or different and are hydrogen, halo, C 1 -C 6 alkyl, 6 6 6 7 6 C 1 -C 4 alkoxy, trifluoromethyl, NO 2 , COR 6 , COOR or NR6R 7 , wherein R and R 7 are the same or different and are hydrogen, C 1 -C 6 alkyl or benzyl; R 5 is hydrogen, CI- 6 alkyl, C 2 - 6 alkenyl, C3- 6 cycloalkyl, (O=C)-CI. 6 alkyl, (O=C)- C 2 - 6 alkenyl, (O=C)-C3- 6 cycloalkyl, wherein said alkyl, alkenyl and 15 cycloalkyl groups can be substituted by 1, 2 or 3 groups selected from halo, C 3 -C 6 cycloalkyl, phenyl or substituted phenyl, and a pharmaceutically acceptable salt thereof.
2. A compound according to Claim 1, wherein R 5 is C 1 -C 6 alkyl, 20 optionally substituted with phenyl or a C 3 -C 6 cycloalkyl group.
3. A compound according to Claim 1 or 2, wherein R 3 is hydrogen, halogen or C1-4 alkoxy. WO 00/75116 PCTIEP00/05783 -50
4. A compound according to any one of Claims 1 to 3, wherein R I is C 1 - 6 alkyl, C 2 - 6 alkenyl or C3- 6 cycloalkyl, optionally substituted by 1, 2 or 3 groups selected from halo, C 3 -C 6 cycloalkyl, phenyl or substituted phenyl, and R 2 is hydrogen.
5 5. A compound according to any one of Claims 1 to 4, wherein R 4 is hydrogen.
6. A compound selected from the group consisting of: 3,4-Dihydro-1 -oxospiro[naphthalene-2(1H),4'-piperidine]; 1'-cyclopropylmethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; 10 1 '-cyclobutylmethyl-3,4-Dihydro-I -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1'-cyclohexylmethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1'-phenylethyl-3,4-Dihydro-1-oxospiro[naphthalene-2(1H),4'-piperidine]; 1'-cyclopropylethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2(1H),4'-piperidine]; 1'-cinnamyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2(1H),4'-piperidine]; 15 1'-(3,3-diphenylpropyl)-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4' piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-5,7-dimethyl-1-oxospiro[naphthalene 2( 1H),4'-piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-6-methoxy-1-oxospiro[naphthalene-2(1H),4' 20 piperidine]; 1l'-(cyclopropylmethyl)-3,4-Dihydro-5-methoxy-1-oxospiro[naphthalene-2(1H),4' piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-7-methoxy-I -oxospiro[naphthalene-2(1H),4' piperidine]; 25 1l'-(cyclopropylmethyl)-3,4-Dihydro-7-nitro-I -oxospiro[naphthalene-2(1H),4' piperidine]; 1l'-(cyclopropylmethyl)-7-Amino-3,4-dihydro-1-oxospiro[naphthalene-2(1H),4' piperidine]; WO 00/75116 PCTIEP00/05783 -51 l'-(cyclopropylmethyl)-7-Chloro-3,4-dihydro--oxospiro[naphthalene- 2 (1H),4' piperidine]; 3,4-dihydro -1 '-methyl-I -oxospiro(naphthalene-2(1H),4'-piperidine); 1'- allyl - 3,4-dihydro -1 -oxospiro(naphthalene-2(1H),4'-piperidine) 5 3,4-dihydro -1'-( 2-methylpropyl)- 1 -oxospiro(naphthalene-2(1 H),4'-piperidine); l'-cyclopropionyl- 3,4-dihydro -1 -oxospiro(naphthalene-2(1H),4'-piperidine); 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine) - 1' (trans-2-phenyl methylcyclopropyl ) ; 3,4-dihydro -l'-benzyl- 1 -oxospiro(naphthalene- 2 (1H),4'-piperidine); 10 3,4-dihydro -1 '-(di-p-fluorobenzhydryl)- 1 -oxospiro(naphthalene-2( 1H),4' piperidine); I'-cyclopropylmethyl- 1,3,4-trihydro -1-hydroxy-spiro(naphthalene-2(1H),4' piperidine); 1 '-cyclopropylmethyl- 1,2,3,4-tetrahydro -spiro(naphthalene-2(1H),4'-piperidine); 15 1 '-cyclopropylmethyl-1,3-dihydro- 1 -oxospiro-[ 2H-indene-2,4'-piperidine] l'-(cyclopropylmethyl)-8,9-dihydrospiro[6H-benzocycloheptene-6,4'-piperidin] 5(7H)-one; l'-cyclopropylmethyl- 3,4-dihydro -4-methyl-I -oxospiro(naphthalene-2(1H),4' piperidine); 20 6-chloro-l1'-cyclopropylmethyl- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine); l'-cyclopropylmethyl- 3,4-dihydro -6-fluoro-l1-oxospiro(naphthalene-2(1H),4' piperidine); 1 '-cyclopropylmethyl- 3,4-dihydro -6,7-dimethoxy- 1 -oxospiro(naphthalene 25 2(1H),4'-piperidine); l'-(1-cyclopropyl- 1-ethyl)- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine); 1'-(3-pentene)- 3,4-dihydro -1-oxospiro(naphthalene-2(1 H),4'-piperidine; 1'-( 3-phenylpropyl )- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine; 30 1 '-cinnamyl- 3,4-dihydro -6-methoxy- I -oxospiro(naphthalene-2(1H),4' piperidine; WO 00/75116 PCT/EP00/05783 -52 1 '-cyclopropylethyl - 3,4-dihydro -5-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; I'-cyclobutylmethyl - 3,4-dihydro -5-methoxy-l-oxospiro(naphthalene-2(1H),4' piperidine; 5 1l'-cyclohexylmethyl - 3,4-dihydro -5-methoxy-1l-oxospiro(naphthalene-2(1H),4' piperidine; l'-cinnamyl - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 1 '-( 2-phenylethyl) - 3,4-dihydro -5-methoxy- 1 -oxospiro(naphthalene-2(1H),4' 10 piperidine; 1 '-( 3-phenylpropyl) - 3,4-dihydro -5-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene 2(1H),4'-piperidine; 15 1 '-cyclopropylethyl - 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2( 1H),4' piperidine; 1'-cyclobutylmethyl - 3,4-dihydro -6-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; l'-cyclohexylmethyl - 3,4-dihydro -6-methoxy- 1-oxospiro(naphthalene-2(1 H),4' 20 piperidine; l'-cinnamyl - 3,4-dihydro -6-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 1 '-( 2-phenylethyl) - 3,4-dihydro -6-methoxy- I -oxospiro(naphthalene-2( 1H),4' piperidine; 25 1 '-( 3-phenylpropyl) - 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -6-methoxy-l-oxospiro(naphthalene 2(1H),4'-piperidine; 1'-cyclopropylethyl- 3,4-dihydro -7-methoxy-l1-oxospiro(naphthalene-2(1H),4' 30 piperidine; l'-cyclobutylmethyl - 3,4-dihydro-7-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; WO 00/75116 PCT/EP00/05783 -53 1 '-cyclohexylmethyl - 3,4-dihydro -7-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 1'-cinnamyl - 3,4-dihydro -7-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 5 1'-( 2-phenylethyl) - 3,4-dihydro -7-methoxy-1-oxospiro(naphthalene-2(1H),4' piperidine; 1 '-( 3-phenylpropyl) - 3,4-dihydro -7-methoxy-1 -oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -7-methoxy-l1-oxospiro(naphthalene 10 2(1H),4'-piperidine; 1 '-cyclopropylethyl - 3,4-dihydro -4-methyl- -oxospiro(naphthalene-2(1H),4' piperidine; l'-cyclobutylmethyl - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' piperidine; 15 l'-cyclohexylmethyl - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' piperidine; 1'-cinnamyl - 3,4-dihydro -4-methyl- 1-oxospiro(naphthalene-2(1H),4'-piperidine; 1'-( 2-phenylethyl) - 3,4-dihydro -4-methyl-I -oxospiro(naphthalene-2(1H),4' piperidine; 20 1'-( 3-phenylpropyl) - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' piperidine; 6-chloro- 1 '-cyclopropylethyl - 3,4-dihydro -1-oxospiro(naphthalene-2(1 H),4' 25 piperidine; 6-chloro -1 '-cyclobutylmethyl - 3,4-dihydro -1-oxospiro(naphthalene-2( 1H),4' piperidine; 6-chloro - I '-cyclohexylmethyl - 3,4-dihydro - I -oxospiro(naphthalene-2( 1H),4' piperidine; 30 6-chloro -1'-cinnamyl - 3,4-dihydro -1-oxospiro(naphthalene-2(1 H),4'-piperidine; 6-chloro -1 '-( 2-phenylethyl) - 3,4-dihydro -1 -oxospiro(naphthalene-2( 1H),4' piperidine; WO 00/75116 PCTIEP00/05783 -54 6-chloro -1'-( 3-phenylpropyl) - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine ; and 6-chloro -1'-( 3,3'diphenylpropyl) - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine. 5 3,4-Dihydro-6-methoxy- 1 -oxospiro[naphthalene-2(1H),4'-piperidine]
7. A compound selected from the group consisting of: 1'-cyclopropylmethyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1'-cyclopropylethyl-3,4-Dihydro- 1-oxospiro[naphthalene-2(1H),4'-piperidine]; 10 1 '-cinnamyl-3,4-Dihydro- I -oxospiro[naphthalene-2( 1H),4'-piperidine]; l'-(3,3-diphenylpropyl)-3,4-Dihydro-l1-oxospiro[naphthalene-2(1H),4' piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-5,7-dimethyl- I -oxospiro[naphthalene 2(1H),4'-piperidine]; 15 1l'-(cyclopropylmethyl)-3,4-Dihydro-6-methoxy-l1-oxospiro[naphthalene-2(1H),4' piperidine]; 1 '-(cyclopropylmethyl)-3,4-Dihydro-5-methoxy- 1-oxospiro[naphthalene-2(1H),4' piperidine]; l'-(cyclopropylmethyl)-3,4-Dihydro-7-methoxy-l1-oxospiro[naphthalene-2(1H),4' 20 piperidine]; I'-(cyclopropylmethyl)-3,4-Dihydro-7-nitro- 1 -oxospiro[naphthalene-2(1H),4' piperidine]; 1l'-(cyclopropylmethyl)-7-Amino-3,4-dihydro-l1-oxospiro[naphthalene-2(1H),4' piperidine]; 25 1 '-(cyclopropylmethyl)-7-Chloro-3,4-dihydro- 1 -oxospiro[naphthalene-2(1H),4' piperidine]; I'-cyclopropylmethyl- 1,3,4-trihydro-1-hydroxy-spiro(naphthalene-2(1H),4' piperidine); 1'-cyclopropylmethyl- 1,2,3,4-tetrahydro -spiro(naphthalene-2(1H),4'-piperidine); 30 l'-cyclopropylmethyl-1,3-dihydro- 1-oxospiro-[ 2H-indene-2,4'-piperidine] 1'-(cyclopropylmethyl)-8,9-dihydrospiro[6H-benzocycloheptene-6,4'-piperidin] 5(7H)-one; WO 00/75116 PCT/EP00/05783 -55 1 '-cyclopropylmethyl- 3,4-dihydro -4-methyl- 1-oxospiro(naphthalene-2(1H),4 piperidine); 6-chloro- 1'-cyclopropylmethyl- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine); 5 1'-cyclopropylmethyl- 3,4-dihydro -6-fluoro- 1 -oxospiro(naphthalene-2(1H),4' piperidine); 1'-cyclopropylmethyl- 3,4-dihydro -6,7-dimethoxy-l-oxospiro(naphthalene 2(1H),4'-piperidine); 1 '-(1 -cyclopropyl- 1-ethyl)- 3,4-dihydro -1 -oxospiro(naphthalene-2( 1H),4' 10 piperidine); 1'-(3-pentene)- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine; 1'-( 3-phenylpropyl )- 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine; l'-cinnamyl- 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 15 1 '-cyclopropylethyl - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 1'-cyclobutylmethyl - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; l'-cinnamyl- 3,4-dihydro -5-methoxy- I -oxospiro(naphthalene-2(1H),4' 20 piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -5-methoxy-l1-oxospiro(naphthalene 2(1H),4'-piperidine; 25 l'-cyclopropylethyl - 3,4-dihydro -6-methoxy-l-oxospiro(naphthalene-2(1H),4' piperidine; 1'-cyclobutylmethyl - 3,4-dihydro -6-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 1'-cinnamyl - 3,4-dihydro -6-methoxy-l-oxospiro(naphthalene-2(1H),4' 30 piperidine; 1 '-( 3-phenylpropyl) - 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; WO 00/75116 PCT/EP00/05783 -56 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -6-methoxy-1-oxospiro(naphthalene 2(1H),4'-piperidine; 1'-cyclopropylethyl - 3,4-dihydro -7-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 5 l'-cinnamyl - 3,4-dihydro -7-methoxy-l-oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -7-methoxy-1-oxospiro(naphthalene-2(1H),4' piperidine; 1'-(3,3'diphenylpropyl) -3,4-dihydro -7-methoxy- 1 -oxospiro(naphthalene 10 2(1H),4'-piperidine; 1 '-cyclopropylethyl -3,4-dihydro-4-methyl- 1 -oxospiro(naphthalene-2( 1H),4' piperidine; 1 '-cyclobutylmethyl -3,4-dihydro -4-methyl-1 -oxospiro(naphthalene-2( 1H),4' piperidine; 15 l'-cinnamyl - 3,4-dihydro -4-methyl- 1-oxospiro(naphthalene-2(1H),4'-piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' piperidine ; 1'-( 3,3'diphenylpropyl) - 3,4-dihydro -4-methyl-l-oxospiro(naphthalene-2(1H),4' piperidine; 20 6-chloro- 1 '-cyclopropylethyl - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine; 6-chloro -1'-cinnamyl - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4'-piperidine; 6-chloro -1'-( 3-phenylpropyl) - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine ; and 25 6-chloro -1'-( 3,3'diphenylpropyl) - 3,4-dihydro -1-oxospiro(naphthalene-2(1H),4' piperidine. 3,4-Dihydro-6-methoxy-l-oxospiro[naphthalene-2(1H),4'-piperidine]
8. A compound selected from the group consisting of: l'-cyclopropylmethyl-3,4-Dihydro-l1-oxospiro[naphthalene-2(1H),4'-piperidine]; 30 1'-cyclopropylethyl-3,4-Dihydro- I -oxospiro[naphthalene-2( 1H),4'-piperidine]; 1'-cinnamyl-3,4-Dihydro- 1 -oxospiro[naphthalene-2( 1H),4'-piperidine]; WO 00/75116 PCT/EP00/05783 -57 1 '-(3,3-diphenylpropyl)-3,4-Dihydro- 1-oxospiro[naphthalene-2(1H),4' piperidine]; I '-(cyclopropylmethyl)-3,4-Dihydro-6-methoxy- 1 -oxospiro[naphthalene-2(1H),4' piperidine]; 5 1'-( 3-phenylpropyl )- 3,4-dihydro -1 -oxospiro(naphthalene-2( 1H),4'-piperidine; 1 '-cyclobutylmethyl - 3,4-dihydro -5-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine 1'-cyclopropylethyl - 3,4-dihydro -6-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine; 10 1 '-cyclobutylmethyl - 3,4-dihydro -6-methoxy- 1 -oxospiro(naphthalene-2(1H),4' piperidine; 1'-( 3-phenylpropyl) - 3,4-dihydro -6-methoxy-l1-oxospiro(naphthalene-2(1H),4' piperidine l'-cyclopropylethyl - 3,4-dihydro -7-methoxy-l1-oxospiro(naphthalene-2(1H),4' 15 piperidine; 3,4-Dihydro-6-methoxy- I -oxospiro[naphthalene-2(1H),4'-piperidine]
9. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 8 admixed with a pharmaceutically acceptable carrier, diluent, or carrier therefor. 20
10. A method for treating a mammal suffering from pain and in need of treatment comprising administering an effective amount of a compound of any one of Claims 1 to 8.
11. A method according to Claim 10 wherein the pain is 25 neuropathic pain.
12. A method according to Claim 10 wherein the pain is diabetic neuropathy. WO 00/75116 PCTIEP00/05783 -58
13. A method for treating a mammal suffering from a seizure disorder comprising administering an effective amount of a compound of any one of Claims 1 to 8.
AU64284/00A 1999-06-07 2000-06-07 Tricyclic analgesics Abandoned AU6428400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13786899P 1999-06-07 1999-06-07
US60137868 1999-06-07
PCT/EP2000/005783 WO2000075116A2 (en) 1999-06-07 2000-06-07 Tricyclic analgesics

Publications (1)

Publication Number Publication Date
AU6428400A true AU6428400A (en) 2000-12-28

Family

ID=22479397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64284/00A Abandoned AU6428400A (en) 1999-06-07 2000-06-07 Tricyclic analgesics

Country Status (21)

Country Link
EP (1) EP1235808A2 (en)
JP (1) JP2003513006A (en)
KR (1) KR20020010923A (en)
CN (1) CN1635998A (en)
AP (1) AP2001002356A0 (en)
AU (1) AU6428400A (en)
BG (1) BG106162A (en)
BR (1) BR0011427A (en)
CA (1) CA2376076A1 (en)
EA (1) EA200101117A1 (en)
HR (1) HRP20010913A2 (en)
HU (1) HUP0203317A2 (en)
IL (1) IL146755A0 (en)
IS (1) IS6175A (en)
MA (1) MA26795A1 (en)
MX (1) MXPA01012694A (en)
NO (1) NO20015966L (en)
PL (1) PL357340A1 (en)
SK (1) SK17512001A3 (en)
TR (1) TR200103531T2 (en)
WO (1) WO2000075116A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
FR2915099B1 (en) * 2007-04-19 2009-06-05 Sanofi Aventis Sa USE OF 4-CYCLOPROPYLMETHOXY-N- (3,5-DICHLORO-1-OXYDO-PYRIDIN-4-YL) -5- (METHOXY) PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF CRANIAL TRAUMATISM
WO2012106499A1 (en) * 2011-02-02 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
GB201416346D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
CN115872873A (en) * 2022-12-29 2023-03-31 上海泰坦科技股份有限公司 Recrystallization purification method of bis (2-bromoethyl) amine hydrobromide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8917069D0 (en) * 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
DK0681571T3 (en) * 1993-01-28 1998-11-23 Merck & Co Inc Spiro-substituted azacyclic compounds as tachykinin receptor antagonists
US5439914A (en) * 1994-02-18 1995-08-08 Merck & Co., Inc. Spirocycles
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US6013644A (en) * 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
IS6175A (en) 2001-11-23
WO2000075116A2 (en) 2000-12-14
MA26795A1 (en) 2004-12-20
CA2376076A1 (en) 2000-12-14
HRP20010913A2 (en) 2003-04-30
AP2001002356A0 (en) 2001-12-31
MXPA01012694A (en) 2003-10-15
CN1635998A (en) 2005-07-06
HUP0203317A2 (en) 2003-02-28
NO20015966D0 (en) 2001-12-06
NO20015966L (en) 2001-12-06
TR200103531T2 (en) 2002-06-21
BR0011427A (en) 2002-03-26
JP2003513006A (en) 2003-04-08
EA200101117A1 (en) 2002-06-27
KR20020010923A (en) 2002-02-06
BG106162A (en) 2002-05-31
SK17512001A3 (en) 2002-11-06
WO2000075116A3 (en) 2002-07-04
PL357340A1 (en) 2004-07-26
EP1235808A2 (en) 2002-09-04
IL146755A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
CA2150123C (en) Aminomethylene substituted non-aromatic heterocycles
US5302599A (en) Therapeutically useful heterocyclic indole compounds
DE3750929T2 (en) Benzo (5,6) cycloheptapyridine, compositions and use.
DE68916699T2 (en) Benzopyridopiperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and use.
DE3888441T2 (en) Benzoxazine compounds and their pharmaceutical application.
JP3803268B2 (en) Azabicycloalkane derivatives and their therapeutic use
DE3882895T2 (en) Imide derivatives, their production and use.
SK46793A3 (en) Regenarative melting tank and method of working
US4977175A (en) 4,5,6,7-tetrahydrobenzimidazole derivatives as 5HT3 -antagonists
AU6428400A (en) Tricyclic analgesics
US20040266802A1 (en) Tricyclic analgesics
US4546107A (en) 1,4-Methano-2-benzazepine derivatives useful as cerebal dysfunction-improving drugs, anti-convulsant, anti-epileptic or anti-anxiety drugs
US5334594A (en) Amphoteric tricyclic compound
WO1989006652A1 (en) Antipsychotic gamma-carboline n-oxides
US5854262A (en) Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US6369074B1 (en) Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
DE68916772T2 (en) 1,7 &#39;- [Imidazo- [1,2-a] pyridine] 5&#39; - (6&#39;H) one derivatives and process for their preparation.
US4578397A (en) Indeno(1,2-b)pyrrole derivatives
US20010023248A1 (en) Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
SK137597A3 (en) 1-£&#39;omega&#39;-(3,4-dihydro-2-naphthalenyl)alkyl| cyclic amine derivatives, process for producing the same, and medicinal composition containing the same
DE2118339A1 (en) Psychotropic piperidinespiro-oxazines and-oxazolidines
US6541502B1 (en) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity
US6541501B2 (en) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta[a]-naphthalenyl derivatives with antipsychotic activity
DE69025274T2 (en) Hexahydro-1H-chino [4,3,2-ef] [1,4] benzoxazepine and related compounds and intermediates for manufacture and use as a medicament
AU610696C (en) Antipsychotic gamma-carboline N-oxides

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period